---
title: è‹¯ä¸™èƒº
description: 
published: true
date: 2026-01-30T09:45:42.953Z
tags: 
editor: markdown
dateCreated: 2026-01-30T06:00:07.974Z
---

[â—€è¿”å›](/è¯ç‰©/home.md)

# è‹¯ä¸™èƒº (Amphetamine)

> ã€Šé€ƒç¦»å¡”ç§‘å¤«ã€‹ä¸­"æ€å¿…å¾—"çš„åŸå‹ï¼Œåœ¨ä¸­å›½å’Œå¤§å¤šæ•°å›½å®¶è¢«ç”¨äºå†›ç”¨å…´å¥‹å‰‚



*æ‘˜è‡ª PsychonautWiki*

| **[æ‘˜è¦è¡¨ï¼šè‹¯ä¸™èƒº](./è‹¯ä¸™èƒº.md "Amphetamine/Summary")** |
| --- |

| è‹¯ä¸™èƒº (Amphetamine) | |
| --- | --- |
| [![Amphetamine.png](/æ–‡ä»¶/Amphetamine.png)](/æ–‡ä»¶/Amphetamine.png) | |
| **åŒ–å­¦å‘½å** | |
| ä¿—å | *Amphetamine, Speed, Adderall, Pep* |
| å–ä»£åç§° | *Î±-Methylphenethylamine* |
| ç³»ç»Ÿåç§° | *(RS)-1-Phenylpropan-2-amine* |
| **åˆ†ç±»å½’å±** | |
| ç²¾ç¥æ´»æ€§åˆ†ç±» | *[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")* |
| åŒ–å­¦åˆ†ç±» | *[è‹¯ä¹™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¹™èƒºç±»ç‰©è´¨.md "Phenethylamine")* |
| **[ç»™è¯é€”å¾„](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Routes of Administration")** | |
| - **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹ã€‚[å‚è§å®‰å…¨ç”¨è¯éƒ¨åˆ†](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/home.md "Responsible drug use")ã€‚ <br> <br> | **[å£æœ](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Oral "Routes of Administration")** |
| | |
| **[å‰‚é‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Dosage")** | |
| [ç”Ÿç‰©åˆ©ç”¨åº¦](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Bioavailability "Dosage") | 75%+[\[1\]](#cite_note-Drugbank_-_Amphetamine-1) |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Threshold "Dosage classification") | 2.5 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Light "Dosage classification") | 5 - 10 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Common "Dosage classification") | 10 - 25 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Strong "Dosage classification") | 25 - 50 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Heavy "Dosage classification") | 50 mg + |
| **[æ—¶é•¿](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Duration")** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Total "Duration") | 6 - 8 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Onset "Duration") | 30 - 45 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Come_up "Duration") | 30 - 135 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Peak "Duration") | 2.5 - 4 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Offset "Duration") | 2 - 3 å°æ—¶ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#After_effects "Duration") | 3 - 6 å°æ—¶ |
| <br> <br> | **[é¼»å¸](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Insufflated "Routes of Administration")** |
| | |
| **[å‰‚é‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Dosage")** | |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Threshold "Dosage classification") | 4 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Light "Dosage classification") | 6 - 15 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Common "Dosage classification") | 15 - 30 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Strong "Dosage classification") | 30 - 50 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Heavy "Dosage classification") | 50 mg + |
| **[æ—¶é•¿](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Duration")** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Total "Duration") | 3 - 6 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Onset "Duration") | 1 - 5 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Come_up "Duration") | 30 - 90 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Peak "Duration") | 1 - 2 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Offset "Duration") | 1.5 - 3 å°æ—¶ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#After_effects "Duration") | 2 - 4 å°æ—¶ |
| <br> <br> <br> <br> | **[é™è„‰æ³¨å°„](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Intravenous "Routes of Administration")** |
| | |
| **[å‰‚é‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Dosage")** | |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Threshold "Dosage classification") | 4 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Light "Dosage classification") | 6 - 15 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Common "Dosage classification") | 15 - 30 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Strong "Dosage classification") | 30 - 50 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Heavy "Dosage classification") | 50 mg + |
| **[æ—¶é•¿](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Duration")** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Total "Duration") | 3 - 6 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Onset "Duration") | 2 - 10 ç§’ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Come_up "Duration") | 2 - 10 ç§’ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Peak "Duration") | 2 - 4 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md#Offset "Duration") | 1 - 2 å°æ—¶ |
| - **[å…è´£å£°æ˜](/å…³äºæœ¬ç«™/è§‚å‰æé†’.md "Disclaimer"):** æœ¬ç«™çš„[å‰‚é‡](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Dosage")ä¿¡æ¯ä»…ä»ç”¨æˆ·å’Œ[èµ„æº](/å…³äºæœ¬ç«™/home.md "Network")æ”¶é›†ï¼Œä»…ç”¨äºæ•™è‚²ç›®çš„ã€‚å®ƒä¸æ˜¯æ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚ | |
| **[ç›¸äº’ä½œç”¨](#Dangerous_interactions)** | |
| é…’ç²¾ | âš ï¸ æ…ç”¨ |
| GHB | ğŸ’” å±é™© |
| GBL | ğŸ’” å±é™© |
| é˜¿ç‰‡ç±» | ğŸ’” å±é™© |
| å¯å¡å›  | ğŸ’” å±é™© |
| å¤§éº» | âš ï¸ æ…ç”¨ |
| å’–å•¡å›  | âš ï¸ æ…ç”¨ |
| æ°¯èƒºé…® | âš ï¸ æ…ç”¨ |
| Methoxetamine | ğŸ’” å±é™© |
| è¿·å¹»å‰‚ | âš ï¸ æ…ç”¨ |
| å³ç¾æ²™èŠ¬ | ğŸ’” å±é™© |
| PCP | ğŸ’” å±é™© |
| 25x-NBOMe | ğŸ’” å±é™© |
| 2C-T-x | ğŸ’” å±é™© |
| 5-MeO-xxT | ğŸ’” å±é™© |
| DOx | âš ï¸ æ…ç”¨ |
| æ›²é©¬å¤š | ğŸ’” å±é™© |
| aMT | âš ï¸ æ…ç”¨ |
| MAOIs | ğŸ’” å±é™© |

**è‹¯ä¸™èƒº**ï¼ˆ**Amphetamine**ï¼Œä¹Ÿç§°ä¸º ***alpha*-methylphenethylamine**ã€**amfetamine**ã€**speed**ï¼Œæˆ–å•†å“å **Adderall**ã€**Dexedrine** å’Œ **Tentin**ï¼‰æ˜¯[è‹¯ä¹™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¹™èƒºç±»ç‰©è´¨.md "Phenethylamine")ç±»åˆ«ä¸­çš„ä¸€ç§ç»å…¸[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ç‰©è´¨ã€‚
å®ƒæ˜¯[è‹¯ä¸™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md "Substituted amphetamines")çš„æ¯ä½“åŒ–åˆç‰©ï¼Œè¿™æ˜¯ä¸€ä¸ªå¤šæ ·åŒ–çš„ç¾¤ä½“ï¼ŒåŒ…æ‹¬[ç”²åŸºè‹¯ä¸™èƒº](./ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")ã€[MDMA](./3,4-äºšç”²åŒæ°§åŸºç”²åŸºè‹¯ä¸™èƒº.md "MDMA")ã€[å¡è¥¿é…®](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/anti-å¡è¥¿é…®ç±».md "Cathinone")å’Œ[å®‰éä»–é…®](https://en.wikipedia.org/wiki/Bupropion "Bupropion")ã€‚å…¶ä½œç”¨æœºåˆ¶æ¶‰åŠä¿ƒè¿›ç¥ç»é€’è´¨[å¤šå·´èƒº](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Dopamine")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/è‚¾ä¸Šè…ºç´ å—ä½“.md "Norepinephrine")çš„é‡Šæ”¾ã€‚[\[2\]](#cite_note-2)

å®ƒäº1887å¹´é¦–æ¬¡åˆæˆï¼Œä½†ç›´åˆ°1929å¹´æ‰å‘ç°å…¶ç²¾ç¥å…´å¥‹ä½œç”¨ã€‚[\[3\]](#cite_note-Heal2013-3) åœ¨1930å¹´ä»£ï¼Œå®ƒä½œä¸ºå‡å……è¡€å‰‚ä»¥â€œBenzedrineâ€çš„åç§°éå¤„æ–¹é”€å”®ã€‚[\[4\]](#cite_note-Rasmussen2006-4) å®ƒè¢«å¹¿æ³›ç”¨äºæ²»ç–—å®¿é†‰ã€å—œç¡ç—‡ã€æŠ‘éƒç—‡å’Œè‚¥èƒ–ç—‡ç­‰ä¸€ç³»åˆ—ç–¾ç—…ã€‚[\[5\]](#cite_note-5) ç”±äºæˆç˜¾å’Œæ»¥ç”¨é—®é¢˜ï¼Œå®ƒæœ€ç»ˆè¢«åˆ—ä¸ºè”åˆå›½1971å¹´ã€Šç²¾ç¥è¯ç‰©å…¬çº¦ã€‹ä¸‹çš„å—æ§ç‰©è´¨ã€‚[\[6\]](#cite_note-6)

è‹¯ä¸™èƒºç°åœ¨ä¸»è¦ä½œä¸ºå¤„æ–¹è¯ç”¨äºæ²»ç–—æ³¨æ„åŠ›ç¼ºé™·å¤šåŠ¨éšœç¢ï¼ˆADHDï¼‰ã€å—œç¡ç—‡å’Œè‚¥èƒ–ç—‡ã€‚[\[7\]](#cite_note-7)[\[8\]](#cite_note-8) åœ¨å…¶ä»–å…´å¥‹å‰‚ä¸­ï¼Œè‹¯ä¸™èƒºæ²»ç–—å¯èƒ½é€šè¿‡å‡å°‘é€šå¸¸ä¸æœªæ¥å—æ²»ç–—çš„ADHDå—è¯•è€…çš„ç¥ç»ç¼ºé™·ç›¸å…³çš„ç¥ç»é€’è´¨ç¼ºä¹ï¼Œä»è€Œå¯¹ADHDæ‚£è€…èµ·åˆ°ç¥ç»ä¿æŠ¤ä½œç”¨ã€‚[\[9\]](#cite_note-9)[\[10\]](#cite_note-10) æ­¤å¤–ï¼Œä½œä¸ºä½“èƒ½å¢å¼ºå‰‚å’Œå¨±ä¹æ€§ç‰©è´¨ï¼Œå®ƒæœ‰ç€å¹¿æ³›çš„éæ³•ä½¿ç”¨ã€‚

[ä¸»è§‚æ•ˆåº”](/å…³äºæœ¬ç«™/home.md "Subjective effects")åŒ…æ‹¬[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md "Stimulation")ã€[ä¸“æ³¨åŠ›å¼ºåŒ–](/è¯æ•ˆ/ä¸“æ³¨åŠ›å¼ºåŒ–.md)ã€[åŠ¨æœºå¢å¼º](/è¯æ•ˆ/åŠ¨æœºå¢å¼º.md)ã€[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md "Increased libido")ã€[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")å’Œ[æ¬£å¿«æ„Ÿ](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Euphoria")ã€‚å®ƒé€šå¸¸æ˜¯å£æœçš„ï¼Œä½†ä¹Ÿå¯ä»¥[é¼»å¸ã€æ³¨å°„æˆ–ç›´è‚ ç»™è¯](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Routes of administration")ã€‚è¾ƒä½å‰‚é‡å€¾å‘äºå¢åŠ æ³¨æ„åŠ›å’Œç”Ÿäº§åŠ›ï¼Œè€Œè¾ƒé«˜å‰‚é‡å€¾å‘äºå¢åŠ ç¤¾äº¤èƒ½åŠ›ã€æ€§æ¬²å’Œæ¬£å¿«æ„Ÿã€‚

è‹¯ä¸™èƒºå…·æœ‰å¾ˆé«˜çš„æ»¥ç”¨æ½œåŠ›ã€‚é•¿æœŸä½¿ç”¨ï¼ˆå³é«˜å‰‚é‡ã€é‡å¤ç»™è¯ï¼‰ä¸[å¼ºè¿«æ€§è¡¥é‡](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Compulsive redosing")ã€è€å—æ€§å‡çº§å’Œå¿ƒç†ä¾èµ–æœ‰å…³ã€‚æ­¤å¤–ï¼Œæ»¥ç”¨ä¸è®¸å¤šå¥åº·çŠ¶å†µæœ‰å…³ï¼Œç‰¹åˆ«æ˜¯å¿ƒè¡€ç®¡é—®é¢˜ï¼Œå¦‚[é«˜è¡€å‹](/è¯æ•ˆ/è¡€å‹å‡é«˜.md "High blood pressure")å’Œä¸­é£é£é™©å¢åŠ ã€‚[\[11\]](#cite_note-11)

å¦‚æœä½¿ç”¨è¯¥ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/home.md "Harm reduction practices")ã€‚

ç›®å½•
--------

* [1 å†å²ä¸æ–‡åŒ–](#History_and_culture)
* [2 åŒ–å­¦](#Chemistry)
    + [2.1 å¯¹æ˜ å¼‚æ„ä½“](#Enantiomers)
* [3 è¯ç†å­¦](#Pharmacology)
* [4 ä¸»è§‚æ•ˆåº”](#Subjective_effects)
    + [4.1 **èº¯ä½“æ•ˆåº”**](#Physical_effects)
    + [4.2 **è§†è§‰æ•ˆåº”**](#Visual_effects)
        - [4.2.1 æ‰­æ›²](#Distortions)
        - [4.2.2 å¹»è§‰çŠ¶æ€](#Hallucinatory_states)
    + [4.3 **è®¤çŸ¥æ•ˆåº”**](#Cognitive_effects)
    + [4.4 **è¯æ•ˆæ®‹ä½™**](#After_effects)
    + [4.5 ä½“éªŒæŠ¥å‘Š](#Experience_reports)
* [5 æ¯’æ€§ä¸å±å®³æ½œåŠ›](#Toxicity_and_harm_potential)
    + [5.1 è‡´æ­»å‰‚é‡](#Lethal_dosage)
    + [5.2 ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ›](#Dependence_and_abuse_potential)
    + [5.3 ç²¾ç¥ç—…](#Psychosis)
    + [5.4 å±é™©çš„ç›¸äº’ä½œç”¨](#Dangerous_interactions)
* [6 è¯•å‰‚æµ‹è¯•ç»“æœ](#Reagent_results)
* [7 æ³•å¾‹åœ°ä½](#Legal_status)
* [8 å¦è§](#See_also)
* [9 å¤–éƒ¨é“¾æ¥](#External_links)
* [10 æ–‡çŒ®](#Literature)
* [11 å‚è€ƒèµ„æ–™](#References)


å†å²ä¸æ–‡åŒ–
-------------------

è‹¯ä¸™èƒºäº1887å¹´åœ¨å¾·å›½ç”±ç½—é©¬å°¼äºšåŒ–å­¦å®¶ LazÄƒr Edeleanu é¦–æ¬¡åˆæˆï¼Œä»–å°†å…¶å‘½åä¸º *phenylisopropylamine*ã€‚[\[12\]](#cite_note-12) ç„¶è€Œï¼Œç›´åˆ°1927å¹´ï¼ŒGordon Alles ç‹¬ç«‹é‡æ–°åˆæˆäº†å®ƒå¹¶å‘ç°å…¶å…·æœ‰æ‹Ÿäº¤æ„Ÿç¥ç»ç‰¹æ€§ï¼Œå…¶å…´å¥‹ä½œç”¨æ‰ä¸ºäººæ‰€çŸ¥ã€‚[\[13\]](#cite_note-13)

1933å¹´åº•ï¼ŒSmith, Kline and French å¼€å§‹ä»¥ Benzedrine çš„åä¹‰é”€å”®å‡å……è¡€å‰‚å¸å…¥å™¨å½¢å¼çš„è‹¯ä¸™èƒºã€‚[\[4\]](#cite_note-Rasmussen2006-4) ç¡«é…¸è‹¯ä¸™èƒºï¼ˆBenzedrine sulfateï¼‰äº3å¹´åæ¨å‡ºï¼Œç”¨äºæ²»ç–—å„ç§åŒ»ç–—çŠ¶å†µï¼ŒåŒ…æ‹¬å—œç¡ç—‡ã€è‚¥èƒ–ç—‡ã€ä½è¡€å‹ã€ä½æ€§æ¬²å’Œæ…¢æ€§ç–¼ç—›ã€‚[\[14\]](#cite_note-14)

åœ¨ç¬¬äºŒæ¬¡ä¸–ç•Œå¤§æˆ˜æœŸé—´ï¼Œç›Ÿå†›å’Œè½´å¿ƒå›½å†›é˜Ÿéƒ½å¹¿æ³›ä½¿ç”¨è‹¯ä¸™èƒºå’Œç”²åŸºè‹¯ä¸™èƒºï¼Œä»¥åˆ©ç”¨å…¶å…´å¥‹å’Œå¢å¼ºä½“èƒ½çš„ä½œç”¨ã€‚[\[15\]](#cite_note-15)[\[16\]](#cite_note-16) éšç€å…¶æˆç˜¾ç‰¹æ€§çš„ä¸ºäººæ‰€çŸ¥ï¼Œå„å›½æ”¿åºœå¼€å§‹å¯¹å…¶é”€å”®å®æ–½ä¸¥æ ¼æ§åˆ¶ã€‚[\[17\]](#cite_note-17)

è‹¯ä¸™èƒºä»åœ¨éæ³•åˆæˆå¹¶åœ¨é»‘å¸‚ä¸Šå‡ºå”®ï¼Œä¸»è¦åœ¨æ¬§æ´²å›½å®¶ã€‚[\[18\]](#cite_note-UNreport-18) åœ¨æ¬§ç›Ÿï¼ˆEUï¼‰æˆå‘˜å›½ä¸­ï¼Œ2013å¹´æœ‰120ä¸‡å¹´è½»äººä½¿ç”¨éæ³•è‹¯ä¸™èƒºæˆ–ç”²åŸºè‹¯ä¸™èƒºã€‚2012å¹´æœŸé—´ï¼Œæ¬§ç›Ÿæˆå‘˜å›½å¢ƒå†…æŸ¥è·äº†çº¦5.9å…¬å¨éæ³•è‹¯ä¸™èƒºï¼›[\[18\]](#cite_note-UNreport-18) åŒæœŸæ¬§ç›Ÿå¢ƒå†…éæ³•è‹¯ä¸™èƒºçš„â€œè¡—å¤´ä»·æ ¼â€ä¸ºæ¯å…‹6-38æ¬§å…ƒã€‚[\[18\]](#cite_note-UNreport-18)

åœ¨æ¬§æ´²ä»¥å¤–ï¼Œè‹¯ä¸™èƒºçš„éæ³•å¸‚åœºè¿œå°äºç”²åŸºè‹¯ä¸™èƒºå’ŒMDMAçš„å¸‚åœºã€‚[\[18\]](#cite_note-UNreport-18)

åŒ–å­¦
---------

è‹¯ä¸™èƒºï¼Œä¹Ÿç§°ä¸º *alpha*-methylphenethylamineï¼Œæ˜¯è‹¯ä¹™èƒºå®¶æ—çš„åˆæˆç‰©è´¨ã€‚è‹¯ä¸™èƒºçš„åŒ–å­¦ç»“æ„ç”±[è‹¯ä¹™èƒº](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¹™èƒºç±»ç‰©è´¨.md "Phenethylamine")ç»„æˆï¼Œå³ä¸€ä¸ªè‹¯ç¯é€šè¿‡ä¹™åŸºé“¾ç»“åˆåˆ°ä¸€ä¸ªæ°¨åŸºï¼ˆNH2ï¼‰åŸºå›¢ä¸Šï¼Œåœ¨RÎ±ä½ç½®æœ‰ä¸€ä¸ªé¢å¤–çš„ç”²åŸºå–ä»£ã€‚åç§°â€œamphetamineâ€æ˜¯ **Î±**lpha**m**ethyl**ph**en**et**hyl**amine** çš„ç¼©å†™ã€‚

å®ƒæ˜¯[è‹¯ä¸™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md "Substituted amphetamines")çš„æ¯ä½“åŒ–åˆç‰©ï¼Œè¿™æ˜¯ä¸€ä¸ªé«˜åº¦å¤šæ ·åŒ–çš„ç¾¤ä½“ï¼ŒåŒ…æ‹¬è¯¸å¦‚[å®‰éä»–é…®](https://en.wikipedia.org/wiki/Bupropion "Bupropion")ã€[èŠ¬ç¾æ›²ç§¦](https://en.wikipedia.org/wiki/Phenmetrazine "Phenmetrazine")ã€[ç”²åŸºè‹¯ä¸™èƒº](./ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")ã€[MDMA](./3,4-äºšç”²åŒæ°§åŸºç”²åŸºè‹¯ä¸™èƒº.md "MDMA") å’Œ [DOx](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¹™èƒºç±»ç‰©è´¨.md "DOx") ç³»åˆ—ç­‰ç‰©è´¨ã€‚

åœ¨å®¤æ¸©ä¸‹ï¼Œçº¯æ¸¸ç¦»ç¢±æ˜¯ä¸€ç§æµåŠ¨ã€æ— è‰²ä¸”æŒ¥å‘æ€§çš„æ¶²ä½“ï¼Œå…·æœ‰ç‰¹å¾æ€§çš„å¼ºçƒˆèƒºå‘³å’Œåˆºé¼»ã€ç‡ƒçƒ§çš„å‘³é“ã€‚[\[19\]](#cite_note-19)

### å¯¹æ˜ å¼‚æ„ä½“

è‹¯ä¸™èƒºæ˜¯ä¸€ç§æ‰‹æ€§åŒ–åˆç‰©ã€‚[å¤–æ¶ˆæ—‹](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Racemic")è‹¯ä¸™èƒºï¼ˆdl-amphetamineï¼‰åŒ…å«ä¸¤ç§å…‰å­¦[å¼‚æ„ä½“](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Isomers")æˆ–[å¯¹æ˜ å¼‚æ„ä½“](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Enantiomers")ï¼š

* [å·¦æ—‹è‹¯ä¸™èƒº](https://en.wikipedia.org/wiki/Levoamphetamine "Levoamphetamine") æ˜¯è‹¯ä¸™èƒºçš„â€œå·¦æ‰‹â€å¯¹æ˜ å¼‚æ„ä½“å½¢å¼ã€‚
* [å³æ—‹è‹¯ä¸™èƒº](https://en.wikipedia.org/wiki/Dextroamphetamine "Dextroamphetamine") æ˜¯è‹¯ä¸™èƒºçš„â€œå³æ‰‹â€å¯¹æ˜ å¼‚æ„ä½“å½¢å¼ã€‚

Adderall å’Œè®¸å¤šå…¶ä»–æ··åˆè‹¯ä¸™èƒºç›åˆ¶å‰‚åŒ…å« d ä¸ l æ¯”ä¾‹ä¸º 3:1 çš„[å¯¹æ˜ å¼‚æ„ä½“](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Enantiomers")ã€‚è¿™æ˜¯é€šè¿‡æ··åˆä¸€ä»½[å¤–æ¶ˆæ—‹](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Racemic")è‹¯ä¸™èƒºå’Œä¸€ä»½[å³æ—‹è‹¯ä¸™èƒº](https://en.wikipedia.org/wiki/Dextroamphetamine "Dextroamphetamine")æ¥å®ç°çš„ã€‚

è¯ç†å­¦
------------

è‹¯ä¸™èƒºé€šè¿‡å¢åŠ å¤§è„‘å¥–åŠ±å’Œæ‰§è¡ŒåŠŸèƒ½é€šè·¯ä¸­[ç¥ç»é€’è´¨](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Neurotransmitters") [å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/è‚¾ä¸Šè…ºç´ å—ä½“.md "Norepinephrine")å’Œ[å¤šå·´èƒº](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Dopamine")çš„ä¿¡å·æ´»åŠ¨æ¥å‘æŒ¥å…¶è¡Œä¸ºæ•ˆåº”ã€‚è‹¯ä¸™èƒºçš„å¼ºåŒ–å’Œæ¿€åŠ±ä½œç”¨ä¸»è¦å½’å› äºä¸­è„‘è¾¹ç¼˜é€šè·¯ä¸­å¤šå·´èƒºèƒ½æ´»æ€§çš„å¢å¼ºã€‚[\[20\]](#cite_note-Nestler2009-20)

è‹¯ä¸™èƒºçš„æ¬£å¿«å’Œè¿åŠ¨åˆºæ¿€ä½œç”¨å–å†³äºå®ƒå¢åŠ çº¹çŠ¶ä½“çªè§¦[å¤šå·´èƒº](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Dopamine")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/è‚¾ä¸Šè…ºç´ å—ä½“.md "Norepinephrine")æµ“åº¦çš„å¹…åº¦å’Œé€Ÿåº¦ã€‚[\[3\]](#cite_note-Heal2013-3)

å®ƒæ˜¯ç—•é‡èƒºç›¸å…³å—ä½“1ï¼ˆTAAR1ï¼‰çš„æœ‰æ•ˆ[å®Œå…¨æ¿€åŠ¨å‰‚](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Agonist")ï¼Œå¹¶ä¸å›Šæ³¡å•èƒºè½¬è¿ä½“2ï¼ˆVMAT2ï¼‰ç›¸äº’ä½œç”¨ã€‚[\[21\]](#cite_note-21)[\[22\]](#cite_note-22)[\[23\]](#cite_note-23) å¯¹TAAR1å’ŒVMAT2çš„è”åˆä½œç”¨å¯¼è‡´çªè§¦ä¸­å¤šå·´èƒºå’Œå»ç”²è‚¾ä¸Šè…ºç´ æµ“åº¦å¢åŠ ï¼Œä»è€Œåˆºæ¿€ç¥ç»å…ƒæ´»åŠ¨ã€‚

[å³æ—‹è‹¯ä¸™èƒº](https://en.wikipedia.org/wiki/Dextroamphetamine "Dextroamphetamine")æ˜¯æ¯”[å·¦æ—‹è‹¯ä¸™èƒº](https://en.wikipedia.org/wiki/Levoamphetamine "Levoamphetamine")æ›´æœ‰æ•ˆçš„TAAR1æ¿€åŠ¨å‰‚ã€‚[\[24\]](#cite_note-24) å› æ­¤ï¼Œå³æ—‹è‹¯ä¸™èƒºäº§ç”Ÿæ¯”å·¦æ—‹è‹¯ä¸™èƒºæ›´å¤§çš„ä¸­æ¢ç¥ç»ç³»ç»Ÿåˆºæ¿€ï¼Œå¤§çº¦å¤šä¸‰åˆ°å››å€ï¼Œä½†å·¦æ—‹è‹¯ä¸™èƒºå…·æœ‰ç¨å¼ºçš„å¿ƒè¡€ç®¡å’Œå¤–å‘¨æ•ˆåº”ã€‚[\[25\]](#cite_note-25)[\[26\]](#cite_note-26)

è‹¯ä¸™èƒºçš„ç¡®åˆ‡ç”Ÿç‰©åˆ©ç”¨åº¦å°šä¸æ¸…æ¥šï¼Œä½†æ®ä¿¡å£æœè¶…è¿‡75%ï¼Œæ³¨å°„æˆ–é¼»å†…ç»™è¯æ›´é«˜[\[27\]](#cite_note-:0-27)ã€‚å…¶å¸æ”¶å’Œæ’æ³„å¯èƒ½ä¾èµ–äºpHå€¼ã€‚ç¢±æ€§å½¢å¼æ›´å®¹æ˜“åœ¨è‚ é“å¸æ”¶ï¼Œæ›´ä¸å®¹æ˜“è¢«è‚¾è„æ’å‡ºï¼Œå¯èƒ½ä¼šå¢åŠ å…¶åŠè¡°æœŸ[\[27\]](#cite_note-:0-27)ã€‚å®ƒé€šè¿‡è‚¾è„æ’æ³„æ’å‡ºï¼Œå°‘é‡ç”±è‚é…¶æ¸…é™¤ã€‚

ä¸»è§‚æ•ˆåº”
------------------

***å…è´£å£°æ˜ï¼š** ä»¥ä¸‹åˆ—å‡ºçš„æ•ˆåº”å¼•ç”¨äº†[***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](/å…³äºæœ¬ç«™/home.md "Subjective effect index") (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºä¼ é—»ä¸­çš„ç”¨æˆ·æŠ¥å‘Šå’Œ[PsychonautWiki](/å…³äºæœ¬ç«™/home.md "PsychonautWiki") [è´¡çŒ®è€…](/å…³äºæœ¬ç«™/home.md "Special:TopUsers")çš„ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…å®ƒä»¬ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡è¾ƒé«˜å‰‚é‡æ›´å®¹æ˜“è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚*åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ è€Œå˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡*** â˜ .*

### **èº¯ä½“æ•ˆåº”**

*   **[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md "Stimulation")** - æ®æŠ¥é“ï¼Œè‹¯ä¸™èƒºéå¸¸æœ‰æ´»åŠ›å’Œåˆºæ¿€æ€§ã€‚å®ƒå¯ä»¥é¼“åŠ±èº«ä½“æ´»åŠ¨ï¼Œå¦‚è·³èˆã€ç¤¾äº¤ã€è·‘æ­¥æˆ–æ¸…æ´ã€‚è‹¯ä¸™èƒºäº§ç”Ÿçš„ç‰¹å®šåˆºæ¿€é£æ ¼å¯ä»¥æè¿°ä¸ºå¼ºè¿«æ€§çš„ã€‚è¿™æ„å‘³ç€åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œä¿æŒé™æ­¢å˜å¾—å›°éš¾æˆ–ä¸å¯èƒ½ã€‚ä¸‹é¢Œç´§å’¬ã€ä¸è‡ªä¸»çš„èº«ä½“é¢¤æŠ–å’Œéœ‡åŠ¨å˜å¾—æ˜æ˜¾ï¼Œå¯¼è‡´å…¨èº«å‰§çƒˆé¢¤æŠ–ã€æ‰‹éƒ¨ä¸ç¨³å’Œç²¾ç»†è¿åŠ¨æ§åˆ¶çš„æ™®éä¸§å¤±ã€‚åœ¨ä½“éªŒç»“æŸæ—¶ï¼Œè¿™ä¼šè¢«è½»åº¦ç–²åŠ³å’Œæ™®éçš„ç–²æƒ«æ‰€å–ä»£ã€‚
*   **[è‡ªå‘æ€§èº¯ä½“æ„Ÿè§‰](/è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md "Spontaneous bodily sensations")** - è‹¯ä¸™èƒºçš„â€œèº«ä½“é«˜æ½®â€å¯ä»¥æè¿°ä¸ºä¸€ç§ä¸­åº¦çš„æ¬£å¿«åˆºç—›æ„Ÿï¼Œè¦†ç›–å…¨èº«ã€‚è¿™ç§æ„Ÿè§‰ä¿æŒç€æŒç»­çš„å­˜åœ¨ï¼Œéšç€èµ·æ•ˆç¨³æ­¥ä¸Šå‡ï¼Œä¸€æ—¦è¾¾åˆ°é¡¶å³°å°±è¾¾åˆ°æé™ã€‚
*   **[èº¯ä½“æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Physical euphoria")**
*   **[å¿ƒå¾‹å¼‚å¸¸](/è¯æ•ˆ/å¿ƒå¾‹å¼‚å¸¸.md "Abnormal heartbeat")**[\[28\]](#cite_note-Sinha2016-28)
*   **[å¿ƒç‡å¢å¿«](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")**[\[28\]](#cite_note-Sinha2016-28)
*   **[è¡€å‹å‡é«˜](/è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")** - çº¦30mmHgæ”¶ç¼©å‹å’Œ20mmHgèˆ’å¼ å‹ï¼Œæ¥è‡ªæœç”¨40mg d-AMPçš„åˆæ¬¡ä½¿ç”¨è€…ã€‚[\[28\]](#cite_note-Sinha2016-28)[\[29\]](#cite_note-Dolder2017-29)
*   **[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")**[\[30\]](#cite_note-30)
*   **[æ”¯æ°”ç®¡æ‰©å¼ ](/è¯æ•ˆ/æ”¯æ°”ç®¡æ‰©å¼ .md "Bronchodilation")**[\[31\]](#cite_note-31)
*   **[è„±æ°´](/è¯æ•ˆ/è„±æ°´.md "Dehydration")**\[*[æ¥æºè¯·æ±‚](/å…³äºæœ¬ç«™/home.md "Citation needed")*\]
*   **[å£å¹²](/è¯æ•ˆ/å£å¹².md "Dry mouth")**[\[32\]](#cite_note-32)
*   **[å°¿é¢‘](/è¯æ•ˆ/å°¿é¢‘.md "Frequent urination")**
*   **[æ’å°¿å›°éš¾](/è¯æ•ˆ/æ’å°¿å›°éš¾.md "Difficulty urinating")**
*   **[ä½“æ¸©å‡é«˜](/è¯æ•ˆ/ä½“æ¸©å‡é«˜.md "Increased bodily temperature")**[\[33\]](#cite_note-33)
*   **[å‡ºæ±—å¢åŠ ](/è¯æ•ˆ/å‡ºæ±—å¢åŠ .md "Increased perspiration")**
*   **[èºç‹‚](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Mania")** - è‹¯ä¸™èƒºå¯åœ¨é—ä¼ æ˜“æ„Ÿä¸ªä½“ä¸­äº§ç”Ÿèºç‹‚ï¼Œä¾‹å¦‚é‚£äº›æ‚£æœ‰[åŒç›¸æƒ…æ„Ÿéšœç¢](http://en.wikipedia.org/wiki/bipolar_disorder "wikipedia:bipolar disorder")æˆ–[ç²¾ç¥åˆ†è£‚ç—‡](http://en.wikipedia.org/wiki/schizophrenia "wikipedia:schizophrenia")çš„äººã€‚è¾ƒé«˜å‰‚é‡å’Œç¡çœ å‰¥å¤ºä¼¼ä¹ä¼šå¢åŠ é£é™©ã€‚
*   **[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md "Nausea")** - å¯ä»¥é€šè¿‡åœ¨æœè¯å‰å’Œæ•´ä¸ªä½“éªŒè¿‡ç¨‹ä¸­è¿›é£Ÿæ¥ç¼“è§£ã€‚
*   **[ç³å­”æ‰©å¤§](/è¯æ•ˆ/ç³å­”æ‰©å¤§.md "Pupil dilation")** - è¿™ç§æ•ˆæœä»…åœ¨ä¸­ç­‰è‡³é«˜å‰‚é‡ä»¥åŠä½å…‰ç…§ä¸‹æ‰ä¼šå‡ºç°ï¼Œå¹¶ä¸”åœ¨è¯æ•ˆæ¶ˆé€€æ—¶æ›´ä¸ºçªå‡ºã€‚
*   **[åå°„æ€§æ™•å¥](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Reflex syncope")**\[*[æ¥æºè¯·æ±‚](/å…³äºæœ¬ç«™/home.md "Citation needed")*\] - è¿™å¯èƒ½æ˜¯ç”±äº[å¿ƒå¾‹å¼‚å¸¸](/è¯æ•ˆ/å¿ƒå¾‹å¼‚å¸¸.md "Effect:Abnormal heartbeat")å¯¼è‡´è¡€å‹çªç„¶ä¸‹é™è€Œç»å†çš„ã€‚
*   **[è€åŠ›å¢å¼º](/è¯æ•ˆ/è€åŠ›å¢å¼º.md "Stamina enhancement")**
*   **[ç£¨ç‰™](/è¯æ•ˆ/ç£¨ç‰™.md "Teeth grinding")** - é«˜å‰‚é‡ä¸‹å¯èƒ½ä¼šå‡ºç°ç£¨ç‰™ã€‚ç„¶è€Œï¼Œå®ƒæ¯”[MDMA](./3,4-äºšç”²åŒæ°§åŸºç”²åŸºè‹¯ä¸™èƒº.md "MDMA")çš„å¼ºåº¦è¦å°ã€‚
*   **[æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢](/è¯æ•ˆ/æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢.md "Temporary erectile dysfunction")**
*   **[è¡€ç®¡æ”¶ç¼©](/è¯æ•ˆ/è¡€ç®¡æ”¶ç¼©.md "Vasoconstriction")**[\[34\]](#cite_note-34) - è‹¯ä¸™èƒºä½¿ç”¨ä¼šå¯¼è‡´è¡€ç®¡æ”¶ç¼©ï¼Œå¯¼è‡´èº«ä½“æŸäº›éƒ¨ä½è¡€æ¶²ä¾›åº”ä¸è¶³ã€‚è¿™å¯èƒ½ä¼šå¯¼è‡´åˆºç—›æˆ–ç–¼ç—›æ„Ÿã€å¯’å†·æ„Ÿã€éº»æœ¨ã€è‹ç™½æˆ–çš®è‚¤é¢œè‰²å˜åŒ–ï¼Œå°¤å…¶æ˜¯åœ¨æ‰‹æŒ‡å’Œè„šè¶¾ã€‚

### **è§†è§‰æ•ˆåº”**

*   è‹¯ä¸™èƒºçš„è§†è§‰æ•ˆåº”ä¸ä¸€è‡´ï¼Œå¹¶ä¸”ä»…åœ¨è¾ƒé«˜å‰‚é‡ä¸‹æ‰ä¼šè½»å¾®æ˜æ˜¾ã€‚å®ƒä»¬åœ¨æŸç§ç¨‹åº¦ä¸Šå¯ä¸[è°µå¦„å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è°µå¦„å‰‚.md "Deliriant")çš„è§†è§‰æ•ˆæœç›¸åª²ç¾ï¼Œå¹¶ä¸”æ›´å®¹æ˜“åœ¨è¾ƒæš—çš„åŒºåŸŸå‘ç”Ÿã€‚

    #### æ‰­æ›²
* **[æ¼‚ç§»](/è¯æ•ˆ/æ¼‚ç§».md "Visual drifting")** - è¿™ç§æ•ˆæœé€šå¸¸å¾ˆå¾®å¦™ï¼Œå‡ ä¹ä¸æ˜æ˜¾ï¼Œåªå‘ç”Ÿåœ¨è¾ƒé«˜å‰‚é‡æˆ–ä¸[å¤§éº»](/è¯ç‰©/å››æ°¢å¤§éº»é…šï¼ˆTHCï¼‰.md "Cannabis")ç»“åˆä½¿ç”¨æ—¶ã€‚é€šå¸¸è¿™åŒ…æ‹¬1-2çº§çš„æ¼‚ç§»ã€‚
* **[äº®åº¦æ”¹å˜](/è¯æ•ˆ/äº®åº¦æ”¹å˜.md "Brightness alteration")** - ç”±äºå…¶ç³å­”æ‰©å¼ ä½œç”¨ï¼Œè‹¯ä¸™èƒºå¯ä»¥ä½¿ç©ºé—´çœ‹èµ·æ¥æ›´äº®ã€‚
* **[æ®‹å½±](/è¯æ•ˆ/æ®‹å½±.md "Tracers")** - ä½å‰‚é‡ä¸‹æ­¤æ•ˆæœä¸å¯å¯Ÿè§‰ã€‚å®ƒåœ¨è¾ƒå¤§å‰‚é‡ä¸‹æœ€ä¸ºæ˜æ˜¾ï¼Œç‰¹åˆ«æ˜¯å½“æŸäººè¢«å‰¥å¤ºç¡çœ æ—¶ï¼Œå¦ä¸€æ–¹é¢è¿™å¾ˆå®¹æ˜“ç”±è¯¥ç‰©è´¨çš„å…¶ä»–å½±å“å¼•å‘ã€‚

    å®ƒåœ¨psychonaut wikié‡è¡¨ä¸Šå¯è¾¾åˆ°çº¦2.5-3ç‚¹ã€‚ï¼ˆç‚¹å‡»ä¸Šé¢çš„æ®‹å½±ä»¥é˜…è¯»æ›´å¤šï¼‰

    #### å¹»è§‰çŠ¶æ€
* **[å˜å½¢](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Transformations")** - è¿™ç§æ•ˆæœéå¸¸ç½•è§ï¼Œé€šå¸¸ä»…å½“ç”¨æˆ·æœç”¨äº†é«˜å‰‚é‡ã€æ­£åœ¨è¯æ•ˆæ¶ˆé€€æˆ–é†’ç€çš„æ—¶é—´å¼‚å¸¸é•¿æ—¶æ‰ä¼šå‘ç”Ÿã€‚å½“å®ƒä»¬å‘ç”Ÿæ—¶ï¼Œé€šå¸¸éå¸¸è½»å¾®ã€‚
* **[å‡ ä½•å›¾å½¢](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Geometry")** - è¿™ç§æ•ˆæœç”±ä¸€äº›è‹¯ä¸™èƒºå’Œç›¸å…³ç‰©è´¨çš„ä½¿ç”¨è€…æŠ¥å‘Šï¼Œé€šå¸¸æ˜¯åœ¨è¾ƒé‡å‰‚é‡ä¸‹è¯•å›¾ç¡è§‰æ—¶ã€‚å®ƒå¯ä»¥è¢«æè¿°ä¸ºç®€å•çš„ã€ç®—æ³•çš„ã€åˆæˆçš„ã€æ˜æš—çš„ã€å¤šè‰²çš„ã€æœ‰å…‰æ³½çš„ã€è¾¹ç¼˜é”‹åˆ©çš„ã€ç¼©å°çš„ã€å…‰æ»‘çš„ã€æœ‰è§’çš„ã€èº«ä¸´å…¶å¢ƒçš„å’Œæ¸è¿›çš„å˜åŒ–ã€‚å®ƒé€šå¸¸å‘ç”Ÿåœ¨3çº§ï¼Œä½†ä¹Ÿå¯èƒ½åœ¨ä¸è¯¸å¦‚[å¤§éº»](/è¯ç‰©/å››æ°¢å¤§éº»é…šï¼ˆTHCï¼‰.md "Cannabis")æˆ–[å³ç¾æ²™èŠ¬](./å³ç¾æ²™èŠ¬.md "DXM")ç­‰ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶å‘å±•åˆ°4çº§å’Œ5çº§ã€‚

### **è®¤çŸ¥æ•ˆåº”**

*   è‹¯ä¸™èƒºçš„è®¤çŸ¥æ•ˆåº”é€šå¸¸è¢«ä¸»è§‚åœ°è®¤ä¸ºæ¯”å…¶ä»–å¼ºæ•ˆ[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")ï¼ˆå¦‚[å¯å¡å› ](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/anti-å¡è¥¿é…®ç±».md "Cocaine")ï¼‰æ›´æ¸…é†’å’Œâ€œåŠŸèƒ½æ€§â€ã€‚åœ¨ä½åˆ°ä¸­ç­‰å‰‚é‡ä¸‹ï¼Œè‹¯ä¸™èƒºçš„å¿ƒå¢ƒå¯ä»¥åœ¨å¾ˆå¤šæ–¹é¢â€œæ¨¡ä»¿æ¸…é†’â€ï¼›å› æ­¤ï¼Œä½¿ç”¨è€…ç”šè‡³æ—è§‚è€…ä¼šè¯¯ä»¥ä¸ºè¿™ç§æ•ˆæœæ˜¯æ›´è‡ªç„¶æˆ–å¹³å‡¡çš„å…´å¥‹å’Œä¸“æ³¨çŠ¶æ€ã€‚è¢«è¯Šæ–­æ‚£æœ‰ADHD/ADDï¼ˆæŸäº›å¤§è„‘åŒºåŸŸ[å¤šå·´èƒº](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Dopamine")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/è‚¾ä¸Šè…ºç´ å—ä½“.md "Norepinephrine")ç¼ºä¹ï¼‰çš„ä¸ªä½“åœ¨ä½æˆ–ä¸­ç­‰å‰‚é‡çš„è‹¯ä¸™èƒºä¸‹å¯èƒ½ä¼šæœ‰æˆªç„¶ä¸åŒçš„ååº”ã€‚

* **[åˆ†æå¢å¼º](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Analysis enhancement")** - ä¸å…¶ä»–å¸¸è§[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")ç›¸æ¯”ï¼Œè¿™ç§æ•ˆæœè¢«è®¤ä¸ºæ›´ä¸€è‡´å’Œæ™®éã€‚
* **[è®¤çŸ¥æ¬£å¿«](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Cognitive euphoria")**
* **[å¼ºè¿«æ€§è¡¥é‡](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Compulsive redosing")** - è¿™ç§è¡Œä¸ºæ•ˆåº”é€šå¸¸æ¯”[å¯å¡å› ](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/anti-å¡è¥¿é…®ç±».md "Cocaine")æ›´ä¸æ˜æ˜¾ï¼Œæˆ–è€…å½“è‹¯ä¸™èƒºæ˜¯é¼»å¸è€Œä¸æ˜¯å£æœæ—¶ã€‚
* **[è‡ªæˆ‘è†¨èƒ€](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Ego inflation")**
* **[æƒ…ç»ªæŠ‘åˆ¶](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Emotion suppression")** - è¿™ç§æ•ˆæœé€šå¸¸åœ¨è½»å¾®å’Œä¸­ç­‰å‰‚é‡æˆ–é¢‘ç¹ä½¿ç”¨æ—¶æœ€ä¸ºå¼ºçƒˆï¼Œå¹¶ä¸”æ›´å¤šåœ°æ¥è‡ªåŒ»ç–—ç”¨é€”è€Œéå¨±ä¹ç”¨é€”çš„æŠ¥å‘Šã€‚
* **[ä¸“æ³¨åŠ›å¼ºåŒ–](/è¯æ•ˆ/ä¸“æ³¨åŠ›å¼ºåŒ–.md)** - è¿™ç§æ•ˆæœåœ¨ä½åˆ°ä¸­ç­‰å‰‚é‡ä¸‹æœ€æœ‰æ•ˆï¼Œå› ä¸ºä»»ä½•æ›´é«˜çš„å‰‚é‡é€šå¸¸ä¼šæŸå®³æ³¨æ„åŠ›æˆ–å¯¼è‡´ä½¿ç”¨è€…å› è¿‡äºæ´»è·ƒæˆ–ç„¦èºä¸å®‰è€Œæ— æ³•é›†ä¸­æ³¨æ„åŠ›ã€‚
* **[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md "Increased libido")** - è™½ç„¶è‹¯ä¸™èƒºçš„ä½¿ç”¨ä¼šå¯¼è‡´æ€§æ¬²å¢å¼ºçš„æ„Ÿè§‰ï¼Œä½†è¡€ç®¡æ”¶ç¼©å¯èƒ½ä¼šå¯¼è‡´éš¾ä»¥å‹ƒèµ·æˆ–ç»´æŒå‹ƒèµ·ã€‚
* **[éŸ³ä¹æ¬£èµå¢å¼º](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Increased music appreciation")**
* **[æ˜“æ€’](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Irritability")** - è¿™æ›´æœ‰å¯èƒ½å‘ç”Ÿåœ¨è¾ƒé«˜å‰‚é‡å’Œ/æˆ–è¯æ•ˆæ¶ˆé€€æœŸé—´ã€‚
* **[è®°å¿†å¢å¼º](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Memory enhancement")**
* **[åŠ¨æœºå¢å¼º](/è¯æ•ˆ/åŠ¨æœºå¢å¼º.md)** - æ®ä¼ é—»ï¼Œå½“[å·¦æ—‹è‹¯ä¸™èƒº](https://en.wikipedia.org/wiki/Levoamphetamine "Levoamphetamine") [å¯¹æ˜ å¼‚æ„ä½“](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Enantiomer")å­˜åœ¨äºè¯¥ç‰©è´¨ä¸­æ—¶ï¼ˆä¾‹å¦‚åœ¨[å¤–æ¶ˆæ—‹](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Racemic")è‹¯ä¸™èƒºæˆ–è¯¸å¦‚Adderallçš„è‹¯ä¸™èƒºç›æ··åˆç‰©ä¸­ï¼‰ï¼Œæ­¤æˆåˆ†ä¼¼ä¹æ›´ä¸ºæ™®éã€‚
* **[ç²¾ç¥ç—…](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Psychosis")** - è¿™ç§æ•ˆæœä»…å‘ç”Ÿåœ¨æ˜“æ„Ÿä¸ªä½“ä¸­ï¼Œæˆ–åœ¨é•¿æœŸã€é«˜é¢‘ä½¿ç”¨åï¼Œæˆ–ç”±äºç¡çœ å‰¥å¤ºã€‚ç„¶è€Œï¼Œé‡å¤ç»™äºˆé˜ˆå€¼/æä½å‰‚é‡ï¼ˆå¦‚2.5mgï¼‰ä¹Ÿå¯èƒ½ä¸è¿™ç§æ•ˆåº”æœ‰å…³ï¼Œå¯èƒ½æ˜¯ç”±äºâ€œå¤šå·´èƒºè¶…æ•ååº”â€å‡è¯´ã€‚ç„¶è€Œï¼Œè¿™ä¸ªè¯é¢˜æœ‰äº›äº‰è®®å’Œæ¨æµ‹æ€§ã€‚
* **[æš—ç¤ºæ€§æŠ‘åˆ¶](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Suggestibility suppression")**
* **[æ€ç»´åŠ é€Ÿ](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Thought acceleration")**
* **[æ€ç»´ç»„ç»‡](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Thought organization")**
* **[æ—¶é—´æ‰­æ›²](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Time distortion")** - è¿™å¯ä»¥æè¿°ä¸ºç”±äº[å¤šå·´èƒº](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Dopamine")æ°´å¹³å¢åŠ ï¼Œä½“éªŒåˆ°æ—¶é—´åŠ é€Ÿå¹¶ä¸”æ¯”æ¸…é†’æ—¶è¿‡å¾—å¿«å¾—å¤šã€‚
* **[æ¸…é†’](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Wakefulness")** - ä¸[ç”²åŸºè‹¯ä¸™èƒº](./ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")ç›¸æ¯”ï¼Œè¯¥æˆåˆ†é€šå¸¸è¢«è®¤ä¸ºå¼ºåº¦è¾ƒå°ï¼Œä½†æ¯”å¯å¡å› æ›´å¼ºçƒˆã€‚

### **è¯æ•ˆæ®‹ä½™**

*   ä¸[è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Peak")æœŸé—´å‘ç”Ÿçš„æ•ˆæœç›¸æ¯”ï¼Œ[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ä½“éªŒçš„[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "Offset")æœŸé—´å‘ç”Ÿçš„æ•ˆæœé€šå¸¸æ„Ÿè§‰æ¶ˆæå’Œä¸èˆ’æœã€‚è¿™é€šå¸¸è¢«ç§°ä¸ºâ€œcomedownâ€æˆ–â€œå´©æºƒâ€ï¼Œå¹¶ä¸”ç”±äº[ç¥ç»é€’è´¨](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Neurotransmitter")ï¼ˆç‰¹åˆ«æ˜¯å„¿èŒ¶é…šèƒºï¼‰è€—å°½è€Œå‘ç”Ÿã€‚å…¶å½±å“é€šå¸¸åŒ…æ‹¬ï¼š

* **[ç„¦è™‘](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Anxiety")** - ä¸€äº›ä½¿ç”¨è€…åœ¨è¯æ•ˆæ¶ˆé€€æœŸé—´ç„¦è™‘å¯èƒ½è¾¾åˆ°ä¸¥é‡æ°´å¹³ã€‚
* **[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")**
* **[è®¤çŸ¥ç–²åŠ³](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Cognitive fatigue")**
* **[æŠ‘éƒ](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Depression")**
* **[å¿ƒç‡å¢å¿«](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")** - è™½ç„¶è‹¯ä¸™èƒºçš„è¡€è¯æµ“åº¦å’Œå¤§å¤šæ•°ä¸»è§‚æ•ˆåº”åœ¨ç»™è¯åçº¦3å°æ—¶æœ€é«˜ï¼Œä½†å¿ƒç‡åœ¨ç»™è¯å10å°æ—¶æ‰è¾¾åˆ°å³°å€¼ã€‚[\[29\]](#cite_note-Dolder2017-29)
* **[æ˜“æ€’](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Irritability")**
* **[ä¸å®è…¿](/è¯æ•ˆ/ä¸å®è…¿.md "Restless legs")**
* **[ç¡çœ ç˜«ç—ª](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Sleep paralysis")** - ä¸€äº›ç”¨æˆ·æŒ‡å‡ºåœ¨æœç”¨è‹¯ä¸™èƒºåå‡ºç°ç¡çœ ç˜«ç—ªã€‚
* **[åšæ¢¦æŠ‘åˆ¶](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Dream suppression")**
* **[æ€ç»´å‡é€Ÿ](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Thought deceleration")**
* **[æ¸…é†’](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Wakefulness")** - ä¸€äº›ç”¨æˆ·åœ¨é‡å¤æœç”¨ä¸€ç³»åˆ—è‹¯ä¸™èƒºå‰‚é‡åçš„å¤±çœ å¯æŒç»­è¶…è¿‡ä¸€å¤©ã€‚
* **[åŠ¨æœºæŠ‘åˆ¶](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Motivation suppression")** - ä½“éªŒèŒƒå›´ä»è½»å¾®çš„åŠ¨åŠ›ä¸è¶³åˆ°æç«¯çš„æ— å…´è¶£çŠ¶æ€ã€‚è¿™ç§æ•ˆæœåœ¨ä¸­ç­‰å’Œä¸¥é‡å‰‚é‡ä¸‹æ›´ä¸ºçªå‡ºã€‚

### ä½“éªŒæŠ¥å‘Š

ç›®å‰æˆ‘ä»¬çš„[ä½“éªŒç´¢å¼•](/æŠ¥å‘Š/psychounautwiki/home.md "Experience index")ä¸­æœ‰2ä»½æè¿°è¯¥ç‰©è´¨æ•ˆåº”çš„ä½“éªŒæŠ¥å‘Šã€‚

*   [Experience:15mg Amphetamine (Oral) - Fairly Pleasant and Productive](/æŠ¥å‘Š/psychounautwiki/Experience:15mg_Amphetamine_(Oral)_-_Fairly_Pleasant_and_Productive.md "Experience:15mg Amphetamine (Oral) - Fairly Pleasant and Productive")
*   [Experience:3-MeO-PCP, LSD, Clonazolam, and Amphetamine - Excessive Amounts and Excessive Confusion](/æŠ¥å‘Š/psychounautwiki/Experience:3-MeO-PCP,_LSD,_Clonazolam,_and_Amphetamine_-_Excessive_Amounts_and_Excessive_Confusion.md "Experience:3-MeO-PCP, LSD, Clonazolam, and Amphetamine - Excessive Amounts and Excessive Confusion")

å…¶ä»–ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

*   [Erowid Experience Vaults: Amphetamine](https://www.erowid.org/experiences/subs/exp_Amphetamines.shtml)

æ¯’æ€§ä¸å±å®³æ½œåŠ›
---------------------------

**æ¯’æ€§å’Œå±å®³æ½œåŠ›éƒ¨åˆ†æ˜¯ä¸€ä¸ª[å­˜æ ¹ã€‚](http://psychonautwiki.org/w/index.php?title=Special%3AWhatLinksHere&target=Template%3AStub&namespace=)**å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´ç”šè‡³**æå…¶é”™è¯¯**çš„ä¿¡æ¯ï¼æ‚¨å¯ä»¥é€šè¿‡[æ‰©å±•æˆ–æ›´æ­£å®ƒ](https://psychonautwiki.org/w/index.php?title=Amphetamine&action=edit)æ¥æä¾›å¸®åŠ©ã€‚
*æ³¨æ„ï¼šå¦‚æœä½¿ç”¨æ­¤ç‰©è´¨ï¼Œè¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶å¹¶ä½¿ç”¨**[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/home.md#General "Responsible drug use")**ã€‚*

[![](https://upload.wikimedia.org/wikipedia/commons/thumb/2/2c/HarmCausedByDrugsTable.png/langen-gb-500px-HarmCausedByDrugsTable.png.png)](/æ–‡ä»¶/HarmCausedByDrugsTable.png)

æ¥è‡ª2010å¹´ISCDç ”ç©¶çš„è¡¨æ ¼ï¼ŒåŸºäºè¯ç‰©å±å®³ä¸“å®¶çš„å£°æ˜å¯¹å„ç§è¯ç‰©ï¼ˆåˆæ³•å’Œéæ³•ï¼‰è¿›è¡Œæ’åã€‚è‹¯ä¸™èƒºè¢«å‘ç°æ˜¯æ€»ä½“ä¸Šç¬¬ä¸ƒå¤§å±é™©è¯ç‰©ã€‚[\[35\]](#cite_note-Nutt_2010-35)

[![](https://psychonautwiki.org/w/thumb.php?f=Harmchart.png&amp;width=300)](/æ–‡ä»¶/Harmchart.png)

æ­¤é›·è¾¾å›¾æ˜¾ç¤ºäº†è‹¯ä¸™èƒºçš„ç›¸å¯¹èº«ä½“ä¼¤å®³ã€ç¤¾ä¼šä¼¤å®³å’Œä¾èµ–æ€§ã€‚[\[36\]](#cite_note-36)

æˆªè‡³2014å¹´3æœˆï¼Œæ²¡æœ‰è¯æ®è¡¨æ˜è‹¯ä¸™èƒºå¯¹äººç±»æœ‰ç›´æ¥çš„ç¥ç»æ¯’æ€§ã€‚[\[37\]](#cite_note-37) ç„¶è€Œï¼Œé«˜å‰‚é‡è‹¯ä¸™èƒºå¯èƒ½ä¼šç”±äºæ´»æ€§æ°§ç±»ç‰©è´¨å¢åŠ çš„æ°§åŒ–åº”æ¿€å’Œå¤šå·´èƒºçš„è‡ªèº«æ°§åŒ–è€Œå¯¼è‡´é—´æ¥çš„ç¥ç»æ¯’æ€§ã€‚[\[20\]](#cite_note-Nestler2009-20)[\[38\]](#cite_note-38)[\[39\]](#cite_note-39)

åœ¨å•®é½¿åŠ¨ç‰©å’Œçµé•¿ç±»åŠ¨ç‰©ä¸­ï¼Œè¶³å¤Ÿé«˜å‰‚é‡çš„è‹¯ä¸™èƒºä¼šå¯¼è‡´å¤šå·´èƒºç¥ç»å…ƒå—æŸï¼Œç‰¹å¾æ˜¯è½¬è¿ä½“å’Œå—ä½“åŠŸèƒ½é™ä½ã€‚[\[40\]](#cite_note-40) é«˜å‰‚é‡è‹¯ä¸™èƒºæš´éœ²å¯¼è‡´çš„ç¥ç»æ¯’æ€§åŠ¨ç‰©æ¨¡å‹è¡¨æ˜ï¼Œé«˜çƒ­ï¼ˆå³æ ¸å¿ƒä½“æ¸© â‰¥ 40 Â°Cï¼‰çš„å‘ç”Ÿæ˜¯è‹¯ä¸™èƒºè¯±å¯¼çš„ç¥ç»æ¯’æ€§å‘å±•çš„å¿…è¦æ¡ä»¶ã€‚[\[41\]](#cite_note-41)

[è¤ªé»‘ç´ ](https://en.wikipedia.org/wiki/Melatonin "Melatonin")å·²è¢«è¯æ˜ï¼ˆå¦‚æœåœ¨æœè¯å‰30åˆ†é’Ÿä»¥ä¸Šä½¿ç”¨ï¼‰å¯ä»¥é¢„é˜²å’Œé€†è½¬è‹¯ä¸™èƒºè¯±å¯¼çš„å¤§é¼ é»‘è´¨TH-pSer40å’Œé’™è›‹ç™½é…¶æŠ‘åˆ¶è›‹ç™½æ°´å¹³çš„[ç¥ç»æ¯’æ€§](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Neurotoxicity")ã€‚[\[42\]](#cite_note-42)[\[43\]](#cite_note-43)

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¯¥ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/home.md "Responsible drug use")ã€‚

### è‡´æ­»å‰‚é‡

è‹¯ä¸™èƒºåœ¨å¤§é¼ ä¸­çš„[LD50](/æ–‡æ¡£/è¯ç‰©æ¦‚è¿°.md "LD50")ï¼ˆæ€æ­»50%æµ‹è¯•å¯¹è±¡æ‰€éœ€çš„å‰‚é‡ï¼‰å¤§çº¦åœ¨æ¯å…¬æ–¤15æ¯«å…‹åˆ°180æ¯«å…‹ä¹‹é—´ï¼Œå…·ä½“å–å†³äºç ”ç©¶ã€‚[\[44\]](#cite_note-44) å°šæœªåœ¨äººç±»ä¸­è¿›è¡Œæ­£å¼ç ”ç©¶ï¼Œç¡®åˆ‡çš„ä¸­æ¯’å‰‚é‡æœªçŸ¥ã€‚

### ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ›

è‹¯ä¸™èƒºå…·æœ‰å¾ˆé«˜çš„æ»¥ç”¨æ½œåŠ›ï¼Œé•¿æœŸä½¿ç”¨å¯èƒ½å¯¼è‡´å¿ƒç†ä¾èµ–ã€‚

å½“äº§ç”Ÿä¾èµ–æ€§æ—¶ï¼Œå¦‚æœçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æ¸´æœ›å’Œ[æˆ’æ–­ååº”](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/æˆ’æ–­ååº”.md "Withdrawal effects")ã€‚[\[45\]](#cite_note-45)[\[46\]](#cite_note-46) æˆ’æ–­ç—‡çŠ¶åŒ…æ‹¬[åæ‰§](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Paranoia")ã€[æŠ‘éƒ](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Depression")ã€[åšæ¢¦å¢å¼º](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Dream potentiation")ã€[ç„¦è™‘](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Anxiety")ã€[ç˜™ç—’æ„Ÿ](/è¯æ•ˆ/ç˜™ç—’æ„Ÿ.md "Itching")ã€[æƒ…ç»ªæ³¢åŠ¨](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Mood swings")ã€[æ˜“æ€’](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Irritability")ã€ç–²åŠ³ã€[å¤±çœ ](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Wakefulness")ä»¥åŠå¯¹æ›´å¤šè‹¯ä¸™èƒºæˆ–å…¶ä»–[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")çš„å¼ºçƒˆæ¸´æœ›ã€‚

å¯¹äºé•¿æœŸæˆ–å¤§é‡å¨±ä¹æ€§ä½¿ç”¨è‹¯ä¸™èƒºè€Œè¨€ï¼Œæˆç˜¾æ˜¯ä¸€ä¸ªä¸¥é‡çš„é£é™©ï¼Œä½†ä¸å¤ªå¯èƒ½ç”±å…¸å‹çš„åŒ»ç–—ç”¨é€”å¼•èµ·ã€‚[\[47\]](#cite_note-47)[\[48\]](#cite_note-48)[\[49\]](#cite_note-49)

éšç€é•¿æœŸå’Œé‡å¤ä½¿ç”¨ï¼Œä¼šå¯¹è‹¯ä¸™èƒºçš„è®¸å¤šæ•ˆæœäº§ç”Ÿè€å—æ€§ã€‚è¿™å¯¼è‡´ç”¨æˆ·å¿…é¡»æœç”¨è¶Šæ¥è¶Šå¤§çš„å‰‚é‡æ‰èƒ½è¾¾åˆ°ç›¸åŒçš„æ•ˆæœã€‚å•æ¬¡ç»™è¯åï¼Œè€å—æ€§éœ€è¦å¤§çº¦3-7å¤©æ‰èƒ½å‡å°‘ä¸€åŠï¼Œ1-2å‘¨æ‰èƒ½æ¢å¤åˆ°åŸºçº¿ï¼ˆåœ¨æ²¡æœ‰è¿›ä¸€æ­¥æ¶ˆè´¹çš„æƒ…å†µä¸‹ï¼‰ã€‚

è‹¯ä¸™èƒºä¸æ‰€æœ‰[å¤šå·´èƒºèƒ½](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Dopamine") [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")è¡¨ç°å‡ºäº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æœç”¨è‹¯ä¸™èƒºåï¼Œå¤§å¤šæ•°[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")çš„æ•ˆæœä¼šé™ä½ã€‚

### ç²¾ç¥ç—…

ä¸»æ¡ç›®ï¼š[å…´å¥‹å‰‚ç²¾ç¥ç—…](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Stimulant psychosis")

ä¸¥é‡çš„è‹¯ä¸™èƒºè¿‡é‡å¯èƒ½å¯¼è‡´å…´å¥‹å‰‚ç²¾ç¥ç—…ï¼Œå¯èƒ½è¡¨ç°å‡ºå„ç§ç—‡çŠ¶ï¼ˆå¦‚[åæ‰§](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Paranoia")ã€[å¹»è§‰](/æ–‡æ¡£/å¹»è§‰ç®€è¿°.md "External hallucinations")ã€[å¦„æƒ³](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Delusions")ï¼‰ã€‚[\[50\]](#cite_note-Cochrane-50) ä¸€é¡¹å…³äºè‹¯ä¸™èƒºæ»¥ç”¨å¼•èµ·çš„ç²¾ç¥ç—…æ²»ç–—çš„ç»¼è¿°æŒ‡å‡ºï¼Œçº¦5-15%çš„ä½¿ç”¨è€…æ— æ³•å®Œå…¨åº·å¤ã€‚[\[50\]](#cite_note-Cochrane-50)[\[51\]](#cite_note-51) åŒä¸€ç¯‡ç»¼è¿°æ–­è¨€ï¼Œ[æŠ—ç²¾ç¥ç—…è¯](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Antipsychotic")è¯ç‰©èƒ½æœ‰æ•ˆè§£å†³æ€¥æ€§è‹¯ä¸™èƒºç²¾ç¥ç—…çš„ç—‡çŠ¶ã€‚[\[50\]](#cite_note-Cochrane-50) ç²¾ç¥ç—…æå°‘ç”±æ²»ç–—æ€§ä½¿ç”¨å¼•èµ·ã€‚[\[52\]](#cite_note-52)

### å±é™©çš„ç›¸äº’ä½œç”¨

***è­¦å‘Šï¼š*** *è®¸å¤šç²¾ç¥æ´»æ€§ç‰©è´¨å•ç‹¬ä½¿ç”¨æ—¶ç›¸å¯¹å®‰å…¨ï¼Œä½†å½“ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶ï¼Œå¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨æä¾›äº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…æ‹¬æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com)ã€[DuckDuckGo](https://www.duckduckgo.com)ã€[PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆå¯ä»¥å®‰å…¨é£Ÿç”¨ã€‚éƒ¨åˆ†åˆ—å‡ºçš„ç›¸äº’ä½œç”¨æ¥æºäº [TripSit](https://combo.tripsit.me)ã€‚*

*   **é…’ç²¾** - åœ¨æœç”¨å…´å¥‹å‰‚æ—¶é¥®é…’è¢«è®¤ä¸ºæ˜¯æœ‰é£é™©çš„ï¼Œå› ä¸ºå®ƒä¼šé™ä½èº«ä½“ç”¨æ¥è¡¡é‡é†‰é…’ç¨‹åº¦çš„é…’ç²¾é•‡é™ä½œç”¨ã€‚è¿™é€šå¸¸ä¼šå¯¼è‡´è¿‡åº¦é¥®é…’ï¼ŒæŠ‘åˆ¶åŠ›å¤§å¤§é™ä½ï¼Œå¢åŠ è‚æŸä¼¤å’Œè„±æ°´çš„é£é™©ã€‚å…´å¥‹å‰‚çš„ä½œç”¨è¿˜ä¼šè®©äººå–åˆ°è¶…è¿‡é€šå¸¸ä¼šæ˜å€’çš„ç¨‹åº¦ï¼Œä»è€Œå¢åŠ é£é™©ã€‚å¦‚æœä½ å†³å®šè¿™æ ·åšï¼Œä½ åº”è¯¥è®¾å®šæ¯å°æ—¶é¥®é…’é‡çš„é™åˆ¶å¹¶ä¸¥æ ¼éµå®ˆï¼Œè®°ä½ä½ ä¼šæ„Ÿè§‰ä¸åˆ°é…’ç²¾å’Œå…´å¥‹å‰‚çš„ä½œç”¨ã€‚
*   **GHB**/**GBL** - å…´å¥‹å‰‚ä¼šå¢åŠ å‘¼å¸é¢‘ç‡ï¼Œå…è®¸æ‘„å…¥æ›´é«˜å‰‚é‡çš„é•‡é™å‰‚ã€‚å¦‚æœå…´å¥‹å‰‚å…ˆå¤±æ•ˆï¼ŒGHB/GBLçš„æŠ‘åˆ¶ä½œç”¨å¯èƒ½ä¼šå‹å€’ä½¿ç”¨è€…å¹¶å¯¼è‡´å‘¼å¸åœæ­¢ã€‚
*   **é˜¿ç‰‡ç±»** - å…´å¥‹å‰‚ä¼šå¢åŠ å‘¼å¸é¢‘ç‡ï¼Œå…è®¸æ‘„å…¥æ›´é«˜å‰‚é‡çš„é˜¿ç‰‡ç±»è¯ç‰©ã€‚å¦‚æœå…´å¥‹å‰‚å…ˆå¤±æ•ˆï¼Œé˜¿ç‰‡ç±»è¯ç‰©å¯èƒ½ä¼šå‹å€’æ‚£è€…å¹¶å¯¼è‡´å‘¼å¸åœæ­¢ã€‚
*   **å¯å¡å› ** - å¯å¡å› çš„å¥–åŠ±ä½œç”¨ç”±DATæŠ‘åˆ¶å’Œé€šè¿‡ç»†èƒè†œçš„å¤šå·´èƒºèƒåä½œç”¨å¢åŠ ä»‹å¯¼ã€‚è‹¯ä¸™èƒºé€šè¿‡pHä»‹å¯¼çš„ç½®æ¢æœºåˆ¶åè½¬DATçš„æ–¹å‘å’Œç»†èƒå†…å›Šæ³¡è½¬è¿çš„æ–¹å‘ï¼Œä»è€Œæ’é™¤äº†é€šè¿‡èƒåä½œç”¨é‡Šæ”¾å¤šå·´èƒºçš„å¸¸è§„æœºåˆ¶ï¼Œå› ä¸ºNa+/K+ ATPé…¶çš„ä½œç”¨è¢«æŠ‘åˆ¶ã€‚ä½ ä¼šå‘ç°å¯å¡å› å’Œè‹¯ä¸™èƒºçš„ç»„åˆä¼šå¯¹å¿ƒè„äº§ç”Ÿå½±å“ï¼Œè¿™æ˜¯ç”±äº5-HT2Béšåçš„æ¿€æ´»å¼•èµ·çš„SERTä»‹å¯¼æœºåˆ¶ï¼Œè¿™æ˜¯è¡€æ¸…ç´ ç›¸å…³ç“£è†œç—…çš„ä¸€ç§å½±å“ã€‚åœ¨æ»¥ç”¨æ¨¡å‹ä¸­ï¼Œè‹¯ä¸™èƒºé€šå¸¸ä¼šå¯¼è‡´é«˜è¡€å‹ï¼Œè¿™ç§ç»„åˆå¯èƒ½ä¼šç”±äºç“£è†œæ“ä½œæœŸé—´çš„æ¹æµè¡€æµè€Œå¢åŠ æ™•å¥çš„æœºä¼šã€‚å¯å¡å› çš„å¥–åŠ±æœºåˆ¶è¢«è‹¯ä¸™èƒºçš„ç»™è¯æ‰€é€†è½¬ã€‚[\[53\]](#cite_note-Greenwald2010-53)[\[54\]](#cite_note-Siciliano2018-54)
*   **å¤§éº»** - å…´å¥‹å‰‚ä¼šå¢åŠ [ç„¦è™‘](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Anxiety")æ°´å¹³ä»¥åŠ[æ€ç»´å¾ªç¯](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Thought loops")å’Œ[åæ‰§](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Paranoia")çš„é£é™©ï¼Œè¿™å¯èƒ½å¯¼è‡´è´Ÿé¢ä½“éªŒã€‚
*   **å’–å•¡å› ** - è¿™ç§å…´å¥‹å‰‚ç»„åˆé€šå¸¸è¢«è®¤ä¸ºæ˜¯ä¸å¿…è¦çš„ï¼Œå¯èƒ½ä¼šå¢åŠ å¿ƒè„è´Ÿæ‹…ï¼Œå¹¶å¯èƒ½å¯¼è‡´ç„¦è™‘å’Œèº«ä½“ä¸é€‚ã€‚
*   **æ›²é©¬å¤š** - æ›²é©¬å¤šå’Œå…´å¥‹å‰‚éƒ½ä¼šå¢åŠ ç™«ç—«å‘ä½œçš„é£é™©ã€‚
*   **å³ç¾æ²™èŠ¬** - ä¸¤ç§ç‰©è´¨éƒ½ä¼šæé«˜å¿ƒç‡ï¼Œåœ¨æç«¯æƒ…å†µä¸‹ï¼Œè¿™äº›ç‰©è´¨å¼•èµ·çš„ææ…Œå‘ä½œå·²å¯¼è‡´æ›´ä¸¥é‡çš„å¿ƒè„é—®é¢˜ã€‚
*   **æ°¯èƒºé…®** - è‹¯ä¸™èƒºå’Œæ°¯èƒºé…®çš„ç»„åˆå¯èƒ½ä¼šå¯¼è‡´ç±»ä¼¼äºç²¾ç¥åˆ†è£‚ç—‡çš„ç²¾ç¥ç—…ï¼Œä½†è¿™å¹¶ä¸æ¯”ä»»ä½•ä¸€ç§ç‰©è´¨å•ç‹¬äº§ç”Ÿçš„ç²¾ç¥ç—…æ›´ä¸¥é‡ï¼Œè¿™ä¸€ç‚¹å°šæœ‰äº‰è®®ã€‚è¿™æ˜¯å› ä¸ºè‹¯ä¸™èƒºèƒ½å¤Ÿå‡å¼±æ°¯èƒºé…®å¼•èµ·çš„å·¥ä½œè®°å¿†ç ´åã€‚è‹¯ä¸™èƒºå•ç‹¬ä½¿ç”¨å¯èƒ½ä¼šå¯¼è‡´å¤¸å¤§ã€åæ‰§æˆ–èº¯ä½“å¦„æƒ³ï¼Œè€Œå¯¹é˜´æ€§ç—‡çŠ¶å‡ ä¹æ²¡æœ‰å½±å“ã€‚ç„¶è€Œï¼Œæ°¯èƒºé…®ä¼šå¯¼è‡´æ€ç»´éšœç¢ã€æ‰§è¡ŒåŠŸèƒ½ç ´åå’Œç”±äºæ¦‚å¿µä¿®æ”¹è€Œäº§ç”Ÿçš„å¦„æƒ³ã€‚è¿™äº›æœºåˆ¶æ˜¯ç”±äºè‹¯ä¸™èƒºé€šè¿‡å½±å“å¤šå·´èƒºçš„è¯ç†ä½œç”¨å¢åŠ äº†ä¸­è„‘è¾¹ç¼˜é€šè·¯ä¸­çš„å¤šå·´èƒºèƒ½æ´»æ€§ï¼Œä»¥åŠç”±äºæ°¯èƒºé…®çš„NMDAæ‹®æŠ—ä½œç”¨ç ´åäº†ä¸­è„‘çš®å±‚é€šè·¯ä¸­çš„å¤šå·´èƒºèƒ½åŠŸèƒ½ã€‚ä¸¤è€…ç»“åˆï¼Œä½ å¯èƒ½ä¼šé¢„æœŸä¸»è¦æ˜¯æ€ç»´éšœç¢ä¼´éšé˜³æ€§ç—‡çŠ¶ã€‚[\[55\]](#cite_note-Krystal2005-55)
*   **PCP** - å¢åŠ å¿ƒåŠ¨è¿‡é€Ÿã€é«˜è¡€å‹å’Œèºç‹‚çŠ¶æ€çš„é£é™©ã€‚
*   **Methoxetamine** - å¢åŠ å¿ƒåŠ¨è¿‡é€Ÿã€é«˜è¡€å‹å’Œèºç‹‚çŠ¶æ€çš„é£é™©ã€‚
*   **è¿·å¹»å‰‚**ï¼ˆä¾‹å¦‚ ***[LSD](./LSD.md "LSD")ã€[éº¦å¸å¡æ—](./éº¦æ–¯å¡æ—.md "Mescaline")ã€[è‡´å¹»è‡](./è‡´å¹»è‡.md "Psilocybin")***ï¼‰ - å¢åŠ [ç„¦è™‘](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Anxiety")ã€[åæ‰§](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Paranoia")å’Œ[æ€ç»´å¾ªç¯](/æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦_ä¸­å¿ƒé¡µ.md "Thought loops")çš„é£é™©ã€‚
    *   **25x-NBOMe** - è‹¯ä¸™èƒºå’ŒNBOMeséƒ½æä¾›ç›¸å½“å¤§çš„åˆºæ¿€ï¼Œå½“ç»“åˆä½¿ç”¨æ—¶ï¼Œå¯èƒ½å¯¼è‡´å¿ƒåŠ¨è¿‡é€Ÿã€é«˜è¡€å‹ã€è¡€ç®¡æ”¶ç¼©ï¼Œåœ¨æç«¯æƒ…å†µä¸‹ä¼šå¯¼è‡´å¿ƒåŠ›è¡°ç«­ã€‚å…´å¥‹å‰‚çš„è‡´ç„¦è™‘å’Œèšç„¦ä½œç”¨ä¸è¿·å¹»å‰‚ç»“åˆä¹Ÿä¸å¥½ï¼Œå› ä¸ºå®ƒä»¬å¯èƒ½å¯¼è‡´ä¸æ„‰å¿«çš„æ€ç»´å¾ªç¯ã€‚å·²çŸ¥NBOMesä¼šå¯¼è‡´ç™«ç—«å‘ä½œï¼Œè€Œå…´å¥‹å‰‚å¯èƒ½ä¼šå¢åŠ è¿™ç§é£é™©ã€‚
    *   **2C-T-x** - æ€€ç–‘å…·æœ‰è½»åº¦MAOIç‰¹æ€§ã€‚å¯èƒ½ä¼šå¢åŠ é«˜è¡€å‹å±è±¡çš„é£é™©ã€‚
    *   **5-MeO-xxT** - æ€€ç–‘å…·æœ‰è½»åº¦MAOIç‰¹æ€§ã€‚å¯èƒ½ä¼šå¢åŠ é«˜è¡€å‹å±è±¡çš„é£é™©ã€‚
    *   **DOx**
*   **aMT** - aMTå…·æœ‰MAOIç‰¹æ€§ï¼Œå¯èƒ½ä¸è‹¯ä¸™èƒºå‘ç”Ÿä¸åˆ©çš„ç›¸äº’ä½œç”¨ã€‚
*   **MAOIs** - MAO-BæŠ‘åˆ¶å‰‚å¯ä»¥ä¸å¯é¢„æµ‹åœ°å¢åŠ è‹¯ä¹™èƒºç±»ç‰©è´¨çš„æ•ˆåŠ›å’ŒæŒç»­æ—¶é—´ã€‚MAO-AæŠ‘åˆ¶å‰‚ä¸è‹¯ä¸™èƒºç»“åˆå¯èƒ½å¯¼è‡´é«˜è¡€å‹å±è±¡ã€‚

è¯•å‰‚æµ‹è¯•ç»“æœ
---------------

å°†åŒ–åˆç‰©æš´éœ²äºè¯•å‰‚ä¸­ä¼šäº§ç”Ÿé¢œè‰²å˜åŒ–ï¼Œè¿™è¡¨æ˜æ­£åœ¨æµ‹è¯•çš„åŒ–åˆç‰©ã€‚

| Marquis | Mecke | Mandelin | Liebermann | Froehde | Robadope |
| --- | --- | --- | --- | --- | --- |
| æ©™è‰² - çº¢è‰² | æ— ååº” | ç¼“æ…¢ï¼ˆæ·±ï¼‰ç»¿è‰² | æ©™è‰² - çº¢è‰² | æ— ååº” | ç²‰è‰² |
| **Ehrlich** | **Hofmann** | **Simonâ€™s** | **Scott** | **Folin** | |
| æ— ååº” | æ— ååº” | æ— ååº” | æ— ååº” | æµ…æ©™è‰² | |

æ³•å¾‹åœ°ä½
------------

åœ¨å›½é™…ä¸Šï¼Œè‹¯ä¸™èƒºï¼ˆåŠå…¶å¼‚æ„ä½“[å³æ—‹è‹¯ä¸™èƒº](https://en.wikipedia.org/wiki/Dextroamphetamine "Dextroamphetamine")å’Œ[å·¦æ—‹è‹¯ä¸™èƒº](https://en.wikipedia.org/wiki/Levoamphetamine "Levoamphetamine")ï¼‰æ˜¯è”åˆå›½1971å¹´ã€Šç²¾ç¥è¯ç‰©å…¬çº¦ã€‹ä¸‹çš„é™„è¡¨IIå—æ§ç‰©è´¨ã€‚[\[56\]](#cite_note-56)

*   **æ¾³å¤§åˆ©äºš**ï¼šè‹¯ä¸™èƒºæ˜¯é™„è¡¨8å—æ§ç‰©è´¨ã€‚[\[57\]](#cite_note-57) æˆªè‡³2023å¹´10æœˆ28æ—¥ï¼Œæ¾³å¤§åˆ©äºšé¦–éƒ½é¢†åœ°ï¼ˆACTï¼‰å°†1.5å…‹ä»¥ä¸‹çš„ä¸ªäººæ•°é‡å»ç½ªåŒ–ã€‚[\[58\]](#cite_note-58)
*   **å¥¥åœ°åˆ©**ï¼šæ ¹æ®SMGï¼ˆå¥¥åœ°åˆ©éº»é†‰å“æ³•ï¼‰ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§å’Œé”€å”®è‹¯ä¸™èƒºæ˜¯éæ³•çš„ã€‚[\[59\]](#cite_note-59)
*   **å·´è¥¿**ï¼šè‹¯ä¸™èƒºæ˜¯A3ç±»ç²¾ç¥æ´»æ€§ç‰©è´¨ã€‚[\[60\]](#cite_note-60)
*   **åŠ æ‹¿å¤§**ï¼šè‹¯ä¸™èƒºåœ¨åŠ æ‹¿å¤§æ˜¯é™„è¡¨Iè¯ç‰©ã€‚[\[61\]](#cite_note-61)
*   **èŠ¬å…°**ï¼šè‹¯ä¸™èƒºæ˜¯è¿ç¦ç‰©è´¨ï¼Œæ ¹æ®èŠ¬å…°éº»é†‰å“æ³•ï¼Œæ‹¥æœ‰ã€è´­ä¹°ã€é”€å”®æˆ–åˆ¶é€ æ˜¯éæ³•çš„ã€‚[\[62\]](#cite_note-62)
*   **æ³•å›½**ï¼šè‹¯ä¸™èƒºè¢«åˆ—ä¸ºâ€œstupÃ©fiantâ€ï¼Œå³å…¬è®¤çš„æ»¥ç”¨è¯ç‰©ã€‚æ‹¥æœ‰ã€è´­ä¹°ã€é”€å”®æˆ–åˆ¶é€ æ˜¯éæ³•çš„ï¼Œä¸”ä¸å¯å¤„æ–¹ã€‚[\[63\]](#cite_note-63)
*   **å¾·å›½**ï¼šè‹¯ä¸™èƒºäº1941å¹´è¢«æ·»åŠ åˆ°é¸¦ç‰‡æ³•ï¼ˆ*Opium Act*ï¼‰ä¸­ã€‚[\[64\]](#cite_note-64) æ ¹æ®1981å¹´çš„éº»é†‰å“æ³•æ”¹é©ï¼Œå®ƒå—Anlage III BtMGï¼ˆ*éº»é†‰å“æ³•ï¼Œé™„è¡¨III*ï¼‰ç®¡åˆ¶ã€‚[\[65\]](#cite_note-65) åªèƒ½é€šè¿‡éº»é†‰å“å¤„æ–¹è¡¨å¼€å…·å¤„æ–¹ã€‚
*   **æ—¥æœ¬**ï¼šè‹¯ä¸™èƒºåœ¨æ—¥æœ¬ç”šè‡³è¢«ç¦æ­¢ç”¨äºåŒ»ç–—ç”¨é€”ã€‚[\[66\]](#cite_note-66)
*   **å¢æ£®å ¡**ï¼šè‹¯ä¸™èƒºæ˜¯ç¦æ­¢ç”¨äºå¨±ä¹ç”¨é€”çš„ç‰©è´¨ã€‚[\[67\]](#cite_note-67)
*   **è·å…°**ï¼šè‹¯ä¸™èƒºæ˜¯æ¸…å•Iå—æ§ç‰©è´¨ã€‚[\[68\]](#cite_note-68)
*   **æ–°è¥¿å…°**ï¼šè‹¯ä¸™èƒºæ˜¯Bç±»å—æ§ç‰©è´¨ã€‚[\[69\]](#cite_note-69)
*   **æ³¢å…°**ï¼šè‹¯ä¸™èƒºæ˜¯II-Pç»„å—æ§ç‰©è´¨ã€‚[\[70\]](#cite_note-70)
*   **éŸ©å›½**ï¼šæ ¹æ®è”åˆå›½ã€Šç²¾ç¥è¯ç‰©å…¬çº¦ã€‹ï¼Œè‹¯ä¸™èƒºåœ¨éŸ©å›½ç”šè‡³è¢«ç¦æ­¢ç”¨äºåŒ»ç–—ç”¨é€”ã€‚[\[71\]](#cite_note-71)
*   **ç‘å…¸**ï¼šè‹¯ä¸™èƒºè¢«è”åˆå›½å½’ç±»ä¸ºè¯ç‰©ï¼Œå¹¶åˆ—å…¥1971å¹´ç²¾ç¥è¯ç‰©å…¬çº¦çš„é™„è¡¨P IIï¼Œä»¥åŠç‘å…¸çš„é™„è¡¨IIã€‚[\[72\]](#cite_note-72)
*   **ç‘å£«**ï¼šè‹¯ä¸™èƒºæ˜¯åœ¨Verzeichnis Aä¸‹ç‰¹åˆ«å‘½åçš„å—æ§ç‰©è´¨ã€‚å…è®¸åŒ»ç–—ä½¿ç”¨ã€‚[\[73\]](#cite_note-73)
*   **æ³°å›½**ï¼šæ ¹æ®2012å¹´æ³°å›½éº»é†‰å“æ³•ï¼Œè‹¯ä¸™èƒºè¢«å½’ç±»ä¸ºç¬¬1ç±»éº»é†‰å“ã€‚[\[74\]](#cite_note-74)
*   **è‹±å›½**ï¼šè‹¯ä¸™èƒºåœ¨è‹±å›½æ˜¯Bç±»è¯ç‰©ã€‚[\[75\]](#cite_note-75)
*   **ç¾å›½**ï¼šè‹¯ä¸™èƒºæ˜¯ç¾å›½çš„é™„è¡¨IIå—æ§ç‰©è´¨ã€‚[\[76\]](#cite_note-76)

å¦è§
--------

*   [å®‰å…¨ç”¨è¯](/æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/home.md "Responsible use")
*   [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")
*   [è‹¯ä¸™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md "Substituted amphetamine")
*   [ç”²åŸºè‹¯ä¸™èƒº](./ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")
*   [å“Œç”²é…¯](./å“Œç”²é…¯.md "Methylphenidate")
*   [MDMA](./3,4-äºšç”²åŒæ°§åŸºç”²åŸºè‹¯ä¸™èƒº.md "MDMA")

å¤–éƒ¨é“¾æ¥
--------------

*   [Amphetamine (Wikipedia)](https://en.wikipedia.org/wiki/Amphetamine)
*   [Amphetamine (Erowid Vault)](https://erowid.org/chemicals/amphetamines/)
*   [Amphetamine (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=2006)
*   [Amphetamine (DrugBank)](https://go.drugbank.com/drugs/DB00182)
*   [Amphetamine (Drugs.com)](https://www.drugs.com/amphetamine.html)

æ–‡çŒ®
----------

*   Galli, A., Poulsen, N.W., Sulzer, D., & Sonders, M.S. (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Progress in Neurobiology, 75 6, 406-33. <https://doi.org/10.1016/j.pneurobio.2005.04.003>
*   Berman, S. M., Kuczenski, R., McCracken, J. T., & London, E. D. (2009). Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 14(2), 123. <https://doi.org/10.1038/mp.2008.90>.
*   Baumann, M., Carroll, F.I., Dersch, C.M., Partilla, J.S., Rothman, R.B., Romero, D., & Rice, K. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39 1, 32-41. doi: 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3

å‚è€ƒèµ„æ–™
----------

1.  [â†‘](#cite_ref-Drugbank_-_Amphetamine_1-0) "[*Drugbank - Amphetamine*](https://go.drugbank.com/drugs/DB00182)
2.  [â†‘](#cite_ref-2) Kish, S. J. (17 June 2008). ["Pharmacologic mechanisms of crystal meth"](http://www.cmaj.ca/cgi/doi/10.1503/cmaj.071675). *Canadian Medical Association Journal*. **178** (13): 1679â€“1682. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1503/cmaj.071675](//doi.org/10.1503%2Fcmaj.071675). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0820-3946](//www.worldcat.org/issn/0820-3946).
3.  â†‘ [3.0](#cite_ref-Heal2013_3-0) [3.1](#cite_ref-Heal2013_3-1) Heal, D. J., Smith, S. L., Gosden, J., Nutt, D. J. (June 2013). ["Amphetamine, past and present â€“ a pharmacological and clinical perspective"](http://journals.sagepub.com/doi/10.1177/0269881113482532). *Journal of Psychopharmacology*. **27** (6): 479â€“496. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1177/0269881113482532](//doi.org/10.1177%2F0269881113482532). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0269-8811](//www.worldcat.org/issn/0269-8811).
4.  â†‘ [4.0](#cite_ref-Rasmussen2006_4-0) [4.1](#cite_ref-Rasmussen2006_4-1) Rasmussen, N. (21 February 2006). ["Making the First Anti-Depressant: Amphetamine in American Medicine, 1929-1950"](https://academic.oup.com/jhmas/article-lookup/doi/10.1093/jhmas/jrj039). *Journal of the History of Medicine and Allied Sciences*. **61** (3): 288â€“323. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/jhmas/jrj039](//doi.org/10.1093%2Fjhmas%2Fjrj039). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0022-5045](//www.worldcat.org/issn/0022-5045).
5.  [â†‘](#cite_ref-5) Angrist, B., Sudilovsky, A. (1978). "Stimulants". In Iversen, L. L., Iversen, S. D., Snyder, S. H. [*Central Nervous System Stimulants: Historical Aspects and Clinical Effects*](https://doi.org/10.1007/978-1-4757-0510-2_3). Handbook of Psychopharmacology. Springer US. pp. 99â€“165. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/978-1-4757-0510-2_3](//doi.org/10.1007%2F978-1-4757-0510-2_3). [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9781475705102](http://en.wikipedia.org/wiki/Special:BookSources/9781475705102 "wikipedia:Special:BookSources/9781475705102").
6.  [â†‘](#cite_ref-6) [*United Nations Treaty Collection*](https://treaties.un.org/Pages/ViewDetails.aspx?src=IND&mtdsg_no=VI-16&chapter=6&clang=_en)
7.  [â†‘](#cite_ref-7) Hodgkins, P., Shaw, M., McCarthy, S., Sallee, F. R. (1 March 2012). "The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter?". *CNS drugs*. **26** (3): 245â€“268. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.2165/11599630-000000000-00000](//doi.org/10.2165%2F11599630-000000000-00000). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1179-1934](//www.worldcat.org/issn/1179-1934).
8.  [â†‘](#cite_ref-8) Billiard, M. (June 2008). ["Narcolepsy: current treatment options and future approaches"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526380/). *Neuropsychiatric Disease and Treatment*. **4** (3): 557â€“566. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1176-6328](//www.worldcat.org/issn/1176-6328).
9.  [â†‘](#cite_ref-9) Sobel, LJ., Bansal, R., Maia, TV., Sanchez, J., Mazzone, L., Durkin, K., Liu, J., Hao, X., Ivanov, I., Miller, A., Greenhill, LL., Peterson, BS. (1 August 2010). "Basal Ganglia Surface Morphology and the Effects of Stimulant Medications in Youth with Attention-Deficit/Hyperactivity Disorder". *The American Journal of Psychiatry*. **167** (8): 977â€“986. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1176/appi.ajp.2010.09091259](//doi.org/10.1176%2Fappi.ajp.2010.09091259).
10. [â†‘](#cite_ref-10) Frodl, T., Skokauskas, N. (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects". *Acta Psychiatrica Scandinavica*. **125** (2): 114â€“26. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/j.1600-0447.2011.01786.x](//doi.org/10.1111%2Fj.1600-0447.2011.01786.x). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [22118249](//www.ncbi.nlm.nih.gov/pubmed/22118249).
11. [â†‘](#cite_ref-11) Westover, A. N., McBride, S., Haley, R. W. (1 April 2007). ["Stroke in Young Adults Who Abuse Amphetamines or Cocaine: A Population-Based Study of Hospitalized Patients"](http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archpsyc.64.4.495). *Archives of General Psychiatry*. **64** (4): 495. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1001/archpsyc.64.4.495](//doi.org/10.1001%2Farchpsyc.64.4.495). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0003-990X](//www.worldcat.org/issn/0003-990X).
12. [â†‘](#cite_ref-12) Edeleano, L. (January 1887). ["Ueber einige Derivate der PhenylmethacrylsÃ¤ure und der PhenylisobuttersÃ¤ure"](https://onlinelibrary.wiley.com/doi/10.1002/cber.188702001142). *Berichte der deutschen chemischen Gesellschaft*. **20** (1): 616â€“622. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/cber.188702001142](//doi.org/10.1002%2Fcber.188702001142). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0365-9496](//www.worldcat.org/issn/0365-9496).
13. [â†‘](#cite_ref-13) Sulzer, D., Sonders, M. S., Poulsen, N. W., Galli, A. (April 2005). ["Mechanisms of neurotransmitter release by amphetamines: A review"](https://linkinghub.elsevier.com/retrieve/pii/S0301008205000432). *Progress in Neurobiology*. **75** (6): 406â€“433. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.pneurobio.2005.04.003](//doi.org/10.1016%2Fj.pneurobio.2005.04.003). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0301-0082](//www.worldcat.org/issn/0301-0082).
14. [â†‘](#cite_ref-14) Bett, W. R. (1 August 1946). ["Benzedrine Sulphate in Clinical Medicine"](https://pmj.bmj.com/lookup/doi/10.1136/pgmj.22.250.205). *Postgraduate Medical Journal*. **22** (250): 205â€“218. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1136/pgmj.22.250.205](//doi.org/10.1136%2Fpgmj.22.250.205). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0032-5473](//www.worldcat.org/issn/0032-5473).
15. [â†‘](#cite_ref-15) Rasmussen, N. (September 2011). ["Medical Science and the Military: The Allies' Use of Amphetamine during World War II"](https://direct.mit.edu/jinh/article/42/2/205-233/50354). *The Journal of Interdisciplinary History*. **42** (2): 205â€“233. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1162/JINH_a_00212](//doi.org/10.1162%2FJINH_a_00212). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0022-1953](//www.worldcat.org/issn/0022-1953).
16. [â†‘](#cite_ref-16) Defalque, R. J., Wright, A. J. (April 2011). ["Methamphetamine for Hitler's Germany: 1937 to 1945"](https://linkinghub.elsevier.com/retrieve/pii/S1522864911500162). *Bulletin of Anesthesia History*. **29** (2): 21â€“32. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S1522-8649(11)50016-2](//doi.org/10.1016%2FS1522-8649%2811%2950016-2). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1522-8649](//www.worldcat.org/issn/1522-8649).
17. [â†‘](#cite_ref-17) "Historical overview of methamphetamine". Vermont Department of Health. Government of Vermont. Archived from the original on 5 October 2012. Retrieved 29 January 2012.
18. â†‘ [18.0](#cite_ref-UNreport_18-0) [18.1](#cite_ref-UNreport_18-1) [18.2](#cite_ref-UNreport_18-2) [18.3](#cite_ref-UNreport_18-3) Mohan, J. (2014), [*World Drug Report 2014*](https://www.unodc.org/wdr2014/), United Nations Office on Drugs and Crime, retrieved 18 August 2014
19. [â†‘](#cite_ref-19) [*PubChem - Amphetamine*](https://pubchem.ncbi.nlm.nih.gov/compound/3007), National Center for Biotechnology Information, retrieved 13 October 2013
20. â†‘ [20.0](#cite_ref-Nestler2009_20-0) [20.1](#cite_ref-Nestler2009_20-1) Nestler, E. J., Hyman, S. E., Malenka, R. C. (2009). *Molecular neuropharmacology: a foundation for clinical neuroscience* (2nd ed ed.). McGraw-Hill Medical. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780071481274](http://en.wikipedia.org/wiki/Special:BookSources/9780071481274 "wikipedia:Special:BookSources/9780071481274"). CS1 maint: Extra text ([link](/w/index.php?title=Category:CS1_maint:_Extra_text&action=edit&redlink=1 "Category:CS1 maint: Extra text (page does not exist)"))
21. [â†‘](#cite_ref-21) Miller, G. M. (January 2011). ["The Emerging Role of Trace Amine Associated Receptor 1 in the Functional Regulation of Monoamine Transporters and Dopaminergic Activity"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101/). *Journal of neurochemistry*. **116** (2): 164â€“176. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/j.1471-4159.2010.07109.x](//doi.org/10.1111%2Fj.1471-4159.2010.07109.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0022-3042](//www.worldcat.org/issn/0022-3042).
22. [â†‘](#cite_ref-22) [*Drugbank - Amphetamine targets*](http://www.drugbank.ca/drugs/DB00182#targets)
23. [â†‘](#cite_ref-23) TA1 receptor | <http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=364>
24. [â†‘](#cite_ref-24) Lewin, A. H., Miller, G. M., Gilmour, B. (December 2011). ["Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class"](https://linkinghub.elsevier.com/retrieve/pii/S0968089611008157). *Bioorganic & Medicinal Chemistry*. **19** (23): 7044â€“7048. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.bmc.2011.10.007](//doi.org/10.1016%2Fj.bmc.2011.10.007). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0968-0896](//www.worldcat.org/issn/0968-0896).
25. [â†‘](#cite_ref-25) Goodman, L. S., Brunton, L. L., Chabner, B., Knollmann, B. C., eds. (2011). *Goodman & Gilmanâ€™s pharmacological basis of therapeutics* (12th ed ed.). McGraw-Hill. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780071624428](http://en.wikipedia.org/wiki/Special:BookSources/9780071624428 "wikipedia:Special:BookSources/9780071624428"). CS1 maint: Extra text ([link](/w/index.php?title=Category:CS1_maint:_Extra_text&action=edit&redlink=1 "Category:CS1 maint: Extra text (page does not exist)"))
26. [â†‘](#cite_ref-26) Eiden, L. E., Weihe, E. (January 2011). ["VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse: VMAT2 and addiction"](https://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2010.05906.x). *Annals of the New York Academy of Sciences*. **1216** (1): 86â€“98. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/j.1749-6632.2010.05906.x](//doi.org/10.1111%2Fj.1749-6632.2010.05906.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0077-8923](//www.worldcat.org/issn/0077-8923).
27. â†‘ [27.0](#cite_ref-:0_27-0) [27.1](#cite_ref-:0_27-1) [*DailyMed - ADDERALL XR- dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate capsule, extended release*](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff45863-ffe1-4d4f-8acf-c7081512a6c0)
28. â†‘ [28.0](#cite_ref-Sinha2016_28-0) [28.1](#cite_ref-Sinha2016_28-1) [28.2](#cite_ref-Sinha2016_28-2) Sinha, A., Lewis, O., Kumar, R., Yeruva, S. L. H., Curry, B. H. (2016). ["Adult ADHD Medications and Their Cardiovascular Implications"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992783/). *Case Reports in Cardiology*. **2016**: 2343691. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1155/2016/2343691](//doi.org/10.1155%2F2016%2F2343691). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [2090-6404](//www.worldcat.org/issn/2090-6404).
29. â†‘ [29.0](#cite_ref-Dolder2017_29-0) [29.1](#cite_ref-Dolder2017_29-1) Dolder, P. C., Strajhar, P., Vizeli, P., Hammann, F., Odermatt, A., Liechti, M. E. (7 September 2017). ["Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594082/). *Frontiers in Pharmacology*. **8**: 617. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.3389/fphar.2017.00617](//doi.org/10.3389%2Ffphar.2017.00617). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1663-9812](//www.worldcat.org/issn/1663-9812).
30. [â†‘](#cite_ref-30) Poulton, A. S., Hibbert, E. J., Champion, B. L., Nanan, R. K. H. (25 April 2016). ["Stimulants for the Control of Hedonic Appetite"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843092/). *Frontiers in Pharmacology*. **7**: 105. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.3389/fphar.2016.00105](//doi.org/10.3389%2Ffphar.2016.00105). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1663-9812](//www.worldcat.org/issn/1663-9812).
31. [â†‘](#cite_ref-31) Nelson, P. E., Moffat, A. C. "Amphetamines and Related Stimulants: Chemical, Biological, Clinical, and Sociological Aspects". [*Detection and Identification of Amphetamine and Related Stimulants*](https://www.taylorfrancis.com/chapters/edit/10.1201/9780429279843-2/detection-identification-amphetamine-related-stimulants-nelson-moffat).
32. [â†‘](#cite_ref-32) Biederman, J., Spencer, T. J., Wilens, T. E., Weisler, R. H., Read, S. C., Tulloch, S. J. (December 2005). "Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD". *CNS spectrums*. **10** (12 Suppl 20): 16â€“25. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1017/s1092852900002406](//doi.org/10.1017%2Fs1092852900002406). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1092-8529](//www.worldcat.org/issn/1092-8529).
33. [â†‘](#cite_ref-33) Pigeau, R, Naitoh, P, Buguet, A, McCann, C, Baranski, J, Taylor, M, Thompson, M, MacK, I (December 1995). "Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature". *Journal of Sleep Research*. **4** (4): 212â€“228. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/j.1365-2869.1995.tb00172.x](//doi.org/10.1111%2Fj.1365-2869.1995.tb00172.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1365-2869](//www.worldcat.org/issn/1365-2869).
34. [â†‘](#cite_ref-34) Broadley, K. J. (1 March 2010). ["The vascular effects of trace amines and amphetamines"](https://www.sciencedirect.com/science/article/pii/S0163725809002174). *Pharmacology & Therapeutics*. **125** (3): 363â€“375. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.pharmthera.2009.11.005](//doi.org/10.1016%2Fj.pharmthera.2009.11.005). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0163-7258](//www.worldcat.org/issn/0163-7258).
35. [â†‘](#cite_ref-Nutt_2010_35-0) Nutt DJ, King LA, Phillips LD (November 2010). "Drug harms in the UK: a multicriteria decision analysis". *Lancet*. **376** (9752): 1558â€“1565. [CiteSeerX](http://en.wikipedia.org/wiki/CiteSeerX "wikipedia:CiteSeerX") [10.1.1.690.1283](//citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.690.1283)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.png/langen-gb-20px-Lock-green.png.png "Freely accessible"). [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S0140-6736(10)61462-6](//doi.org/10.1016%2FS0140-6736%2810%2961462-6). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [21036393](//www.ncbi.nlm.nih.gov/pubmed/21036393). Unknown parameter `|s2cid=` ignored ([help](/w/index.php?title=Help:CS1_errors&action=edit&redlink=1 "Help:CS1 errors (page does not exist)"))
36. [â†‘](#cite_ref-36) Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (24 March 2007). ["Development of a rational scale to assess the harm of drugs of potential misuse"](https://www.sciencedirect.com/science/article/pii/S0140673607604644). *The Lancet*. **369** (9566): 1047â€“1053. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S0140-6736(07)60464-4](//doi.org/10.1016%2FS0140-6736%2807%2960464-4). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0140-6736](//www.worldcat.org/issn/0140-6736).
37. [â†‘](#cite_ref-37) Human health effects - Amphetamine | <http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9>
38. [â†‘](#cite_ref-38) Carvalho, M., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., RemiÃ£o, F., Carvalho, F., Bastos, M. de L. (1 August 2012). ["Toxicity of amphetamines: an update"](https://doi.org/10.1007/s00204-012-0815-5). *Archives of Toxicology*. **86** (8): 1167â€“1231. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/s00204-012-0815-5](//doi.org/10.1007%2Fs00204-012-0815-5). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1432-0738](//www.worldcat.org/issn/1432-0738).
39. [â†‘](#cite_ref-39) Miyazaki, I., Asanuma, M. (June 2008). "Dopaminergic neuron-specific oxidative stress caused by dopamine itself". *Acta Medica Okayama*. **62** (3): 141â€“150. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.18926/AMO/30942](//doi.org/10.18926%2FAMO%2F30942). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0386-300X](//www.worldcat.org/issn/0386-300X).
40. [â†‘](#cite_ref-40) Advokat, C. (July 2007). ["Literature Review: Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD"](http://journals.sagepub.com/doi/10.1177/1087054706295605). *Journal of Attention Disorders*. **11** (1): 8â€“16. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1177/1087054706295605](//doi.org/10.1177%2F1087054706295605). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1087-0547](//www.worldcat.org/issn/1087-0547).
41. [â†‘](#cite_ref-41) Bowyer, J. F., Hanig, J. P. (14 November 2014). ["Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008711/). *Temperature: Multidisciplinary Biomedical Journal*. **1** (3): 172â€“182. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.4161/23328940.2014.982049](//doi.org/10.4161%2F23328940.2014.982049). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [2332-8940](//www.worldcat.org/issn/2332-8940).
42. [â†‘](#cite_ref-42) Chetsawang, J., Mukda, S., Srimokra, R., Govitrapong, P., Chetsawang, B. (3 July 2017). ["Role of Melatonin in Reducing Amphetamine-Induced Degeneration in Substantia Nigra of Rats via Calpain and Calpastatin Interaction"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562346/). *Journal of Experimental Neuroscience*. **11**: 1179069517719237. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1177/1179069517719237](//doi.org/10.1177%2F1179069517719237). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1179-0695](//www.worldcat.org/issn/1179-0695).
43. [â†‘](#cite_ref-43) Leeboonngam, T., Pramong, R., Sae-Ung, K., Govitrapong, P., Phansuwan-Pujito, P. (April 2018). "Neuroprotective effects of melatonin on amphetamine-induced dopaminergic fiber degeneration in the hippocampus of postnatal rats". *Journal of Pineal Research*. **64** (3). [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/jpi.12456](//doi.org/10.1111%2Fjpi.12456). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1600-079X](//www.worldcat.org/issn/1600-079X).
44. [â†‘](#cite_ref-44) Amphetamine - human health effects | <http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3287>
45. [â†‘](#cite_ref-45) [*Amphetamines: Drug Use and Abuse: Merck Manual Home Edition*](http://web.archive.org/web/20070217053619/http://www.merck.com/mmhe/sec07/ch108/ch108g.html), 2007
46. [â†‘](#cite_ref-46) PÃ©rez-MaÃ±Ã¡, C., Castells, X., Torrens, M., CapellÃ , D., Farre, M. (2 September 2013). Cochrane Drugs and Alcohol Group, ed. ["Efficacy of psychostimulant drugs for amphetamine abuse or dependence"](https://doi.wiley.com/10.1002/14651858.CD009695.pub2). *Cochrane Database of Systematic Reviews*. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/14651858.CD009695.pub2](//doi.org/10.1002%2F14651858.CD009695.pub2). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1465-1858](//www.worldcat.org/issn/1465-1858).
47. [â†‘](#cite_ref-47) "Adderall XR Prescribing Information" | <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf>
48. [â†‘](#cite_ref-48) Stolerman, I. P., ed. (2010). *Encyclopedia of psychopharmacology*. Springer. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9783540687092](http://en.wikipedia.org/wiki/Special:BookSources/9783540687092 "wikipedia:Special:BookSources/9783540687092").
49. [â†‘](#cite_ref-49) "Miscellaneous Sympathomimetic Agonists" | <http://accessmedicine.mhmedical.com/content.aspx?bookid=374&sectionid=41266218&jumpsectionID=41268855>
50. â†‘ [50.0](#cite_ref-Cochrane_50-0) [50.1](#cite_ref-Cochrane_50-1) [50.2](#cite_ref-Cochrane_50-2) Shoptaw, S. J., Kao, U., Ling, W. (21 January 2009). Cochrane Drugs and Alcohol Group, ed. ["Treatment for amphetamine psychosis"](https://doi.wiley.com/10.1002/14651858.CD003026.pub3). *Cochrane Database of Systematic Reviews*. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/14651858.CD003026.pub3](//doi.org/10.1002%2F14651858.CD003026.pub3). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1465-1858](//www.worldcat.org/issn/1465-1858).
51. [â†‘](#cite_ref-51) Hofmann, F. G. (1983). *A handbook on drug and alcohol abuse: the biomedical aspects* (2nd ed ed.). Oxford University Press. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780195030563](http://en.wikipedia.org/wiki/Special:BookSources/9780195030563 "wikipedia:Special:BookSources/9780195030563"). CS1 maint: Extra text ([link](/w/index.php?title=Category:CS1_maint:_Extra_text&action=edit&redlink=1 "Category:CS1 maint: Extra text (page does not exist)"))
52. [â†‘](#cite_ref-52) <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf>
53. [â†‘](#cite_ref-Greenwald2010_53-0) Greenwald, M. K., Lundahl, L. H., Steinmiller, C. L. (December 2010). ["Sustained Release d-Amphetamine Reduces Cocaine but not 'Speedball'-Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers"](http://www.nature.com/articles/npp2010175). *Neuropsychopharmacology*. **35** (13): 2624â€“2637. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1038/npp.2010.175](//doi.org/10.1038%2Fnpp.2010.175). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0893-133X](//www.worldcat.org/issn/0893-133X).
54. [â†‘](#cite_ref-Siciliano2018_54-0) Siciliano, C. A., Saha, K., Calipari, E. S., Fordahl, S. C., Chen, R., Khoshbouei, H., Jones, S. R. (10 January 2018). ["Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation"](https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.2604-17.2017). *The Journal of Neuroscience*. **38** (2): 484â€“497. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1523/JNEUROSCI.2604-17.2017](//doi.org/10.1523%2FJNEUROSCI.2604-17.2017). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0270-6474](//www.worldcat.org/issn/0270-6474).
55. [â†‘](#cite_ref-Krystal2005_55-0) Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., Dâ€™Souza, D. C. (1 September 2005). ["Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function"](http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archpsyc.62.9.985). *Archives of General Psychiatry*. **62** (9): 985. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1001/archpsyc.62.9.985](//doi.org/10.1001%2Farchpsyc.62.9.985). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0003-990X](//www.worldcat.org/issn/0003-990X).
56. [â†‘](#cite_ref-56) ["CONVENTION ON PSYCHOTROPIC SUBSTANCES 1971"](http://www.emcdda.europa.eu/system/files/attachments/10451/convention_1971_en.pdf) (PDF). United Nations. Retrieved December 19, 2019.
57. [â†‘](#cite_ref-57) ["POISONS STANDARD DECEMBER 2019"](https://www.legislation.gov.au/Details/F2019L01471). Office of Parliamentary Counsel. Retrieved December 19, 2019.
58. [â†‘](#cite_ref-58) <https://www.health.act.gov.au/about-our-health-system/population-health/drug-law-reform>
59. [â†‘](#cite_ref-59) <https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011053>
60. [â†‘](#cite_ref-60) <https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992>
61. [â†‘](#cite_ref-61) Controlled Drugs and Substances Act | <http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-24.html#h-28>
62. [â†‘](#cite_ref-62) [*Valtioneuvoston asetus huumausaineina pidettÃ¤vistÃ¤ aineista, valmisteista ja kasveista*](https://www.finlex.fi/fi/laki/ajantasa/2008/20080543)
63. [â†‘](#cite_ref-63) [*ArrÃªtÃ© du 22 fÃ©vrier 1990 fixant la liste des substances classÃ©es comme stupÃ©fiants*](https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/)
64. [â†‘](#cite_ref-64) ["Sechste Verordnung Ã¼ber die Unterstellung weiterer Stoffe unter die Bestimmungen des Opiumgesetzes"](https://upload.wikimedia.org/wikipedia/commons/e/ee/Deutsches_Reichsgesetzblatt_41T1_067_0328.jpg) (in German). Reichsministerium des Innern. Retrieved December 25, 2019.
65. [â†‘](#cite_ref-65) ["Anlage III BtMG"](https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 19, 2019.
66. [â†‘](#cite_ref-66) [*UNODC - Bulletin on Narcotics - 1957 Issue 3 - 002*](//www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1957-01-01_3_page003.html)
67. [â†‘](#cite_ref-67) [*RÃ¨glement grand-ducal du 20 mars 1974 concernant certaines substances psychotropes*](https://legilux.public.lu/eli/etat/leg/rgd/1974/03/20/n1/jo)
68. [â†‘](#cite_ref-68) ["Opiumwet"](https://wetten.overheid.nl/BWBR0001941/2009-07-01) (in Dutch). Ministerie van Binnenlandse Zaken en Koninkrijksrelaties. Retrieved December 19, 2019.
69. [â†‘](#cite_ref-69) ["Schedule 2 - Class B controlled drugs"](http://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436586.html). Parliamentary Counsel Office. Retrieved December 19, 2019.
70. [â†‘](#cite_ref-70) [*Ustawa z dnia 24 kwietnia 2015 r. o zmianie ustawy o przeciwdziaÅ‚aniu narkomanii oraz niektÃ³rych innych ustaw (Dz.U. z 2015 r. poz. 875).*](https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20150000875)
71. [â†‘](#cite_ref-71) <https://web.archive.org/web/20160331074842/https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=VI-16&chapter=6&lang=en>
72. [â†‘](#cite_ref-72) LÃ¤kemedelsverkets fÃ¶reskrifter (LVFS 1997:12) om fÃ¶rteckningar Ã¶ver narkotika, konsoliderad version till och med LVFS 2010:1
73. [â†‘](#cite_ref-73) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
74. [â†‘](#cite_ref-74) Thai Narcotic Act of 2012 | <http://narcotic.fda.moph.go.th/faq/upload/Thai%20Narcotic%20Act%202012.doc._37ef.pdf>
75. [â†‘](#cite_ref-75) [*Misuse of Drugs Act 1971*](https://www.legislation.gov.uk/ukpga/1971/38/schedule/2)
76. [â†‘](#cite_ref-76) Controlled Drugs and Substances Act | <http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htm>